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ABSTRACT 
 
The number of cases of Clostridium difficile infection (CDI) has been increasing 
globally. CDI is the main cause of nosocomial diarrhoea, which may be life-
threatening in complicated cases, and also costs the health care societies millions of 
pounds annually. The predominant types and their res stance to antibiotics have been 
changing and one of the major selective pressures which causes this is antimicrobial 
use. Although much is known about the role of the toxins in pathogenesis of CDI, the 
role of immunogenic cell wall components is unclear.  They may play a role in 
colonisation and pathology and a study of these could clarify the infection process. It 
is therefore important to study the immune responses against these bacterial wall 
components from different strains and their effects on stimulation of leukocytes to 
produce cytokines and chemokines.  
 
This study was divided into four parts:  
1. An epidemiological study to determine frequencies of the predominant types of C.
difficile, thus 140 C. difficile isolates from surgical patients and their environme t 
during 2009 were investigated to define their PCR ribotype. This utilised capillary 
sequencing gel electrophoresis for their analysis.  
2. The determination of antimicrobial susceptibility to six antibiotics (ampicillin, 
erythromycin, tetracycline, metronidazole, moxifloxacin and vancomycin) was 
assessed and MIC determination by agar dilutions.  
3. Investigation of host immunity to molecules with conserved molecular patterns. 
Surface-layer proteins (SLPs), lipocarbohydrate (LC) and flagellar proteins were 
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separated and purified from five ribotypes of C. difficile (001, 002, 027, 078 and106) 
predominant in Scotland.  
 
a) The immune responses to these molecules were assessed by ELISA by exposing 
serum of patients and healthy donors and measuring specific IgG levels.  
b) Innate immunity was investigated by distinguishing responses of a macrophage 
cell line (THP1) to the above molecules. Induction of interleukins (IL)-1β, IL-6, IL-
8, IL-10 and IL-12 interleukins and TNF-α was detected by ELISA. 
 
In this study 15 different ribotypes were identified. The most frequent were 001, 020, 
106 ribotypes (52.8%, 7.4% and 5.7%), respectively, while 13 isolates could not be 
assigned a ribotype. However, all isolates were sensitive to vancomycin, 
metronidazole and moxifloxacin, but 74.28% of isolates were resistant to 
erythromycin.  
 
The IgG level against bacterial antigens (SLPs, LC and flagella proteins) in donors’ 
serum showed almost normal distribution to all antigens from the different ribotypes 
and the sensitivity of the assays was increased by raising the concentration of 
antigens. Levels to SLPs were generally the highest, bu  the flagellar protein 
exceeded the SLPs of the 027 ribotype. The donors, c ntrols, patients and carrier sera 
gave similar results.  
 
The greatest induction of interleukins was obtained using 50µg of antigen with the 
THP-1 cells activated with 50ng of PMA. The highest induction of all antigens was 
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for IL-10. The highest values for the control LPS was with IL-12. But the best effect 
for SLPs of 027 was for IL-10 (109.1ng/ml), while the weakest for TNF for SLPs of 
027 (4.7ng/ml). In general the IL-1β, IL-6, IL-8 and TNF concentrations ranged from 
4.7-60ng/ml for all antigens and in contrast IL-12 and IL-10 average ranged 11-
109.1ng/ml. 
 
To conclude, the prevalence ofC. difficile and their antibiotic susceptibility are 
constantly changing. IgG antibodies to SLPs and flagel r proteins from the 
hypervirulent ribotype 027 were highest in the community and hospitalized 
individuals. The molecules of conserved molecular ptterns are immunogenic with 
various levels of response in the monocytic THP1 cells. SLPs were best in inducing 
interleukins. Flagellar proteins from 027 ribotypes accompanied SLPs in IL-10 
induction levels. Consequently SLPs and flagellar proteins from 027 ribotypes 
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1.1 Clostridium difficile epidemiology: 
 
The gut's microbiota is critically important as it spreads to varying degrees in the 
four gastrointestinal areas: stomach, jejunum, ileum and colon. Furthermore, the 
normal gut microorganisms are useful in food processing, assisting intestinal blood 
vessels, stimulating progress of the gut-associated lymphoid tissue (GALT), and 
contributing to organising bowel immunity.  
 
Clostridia are rare in the stomach and jejunum, yet thrive in the colon (Albright and 
Albright, 2009). While the presence of C. difficile in the large intestinal microbiota is 
commensal in most neonates as well as is in about 3% of healthy adults, colonisation 
increases up to 40% in the hospitalised elderly patients or debilitated host; C. difficile 
omnipresence is natural. Moreover, it is the main cause of diarrhoea in long-stay 
hospitalised elderly patients, no doubt due to their consumption of broad-spectrum 
antibiotics. Susceptibility increases in compromised patients. However, the severity 
of symptoms ranges from mild to severe colitis with pseudomembranes and toxic 
megacolon. It may be life-threatening (Sydnor and Perl, 2011).  
 
The first time C. difficile was described as being the main factor of antimicrob al-
associated diarrhoea and pseudomembranous colitis (PMC) was in 1978 (Larson HE 
et al 1978). This was the start of many experts studying pathogenicity, epidemiology, 
risk factors, antibiotic susceptibility, as well as prevention of this infection. 
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C. difficile may be isolated from soil, fresh, salt and tap water, domestic animals and 
all foods including meat, vegetables and animal foods (Al Saif and Brazier, 1996). 
Also, hospital environments could be contaminated by C. difficile spores in 
lavatories, sluice rooms, beds and floors (McCoubrey et al., 2003). Furthermore, 
health-care workers are able to be a source of spore , and long hospitalisation could 
raise the rates of non-symptomatic C. difficile colonisation by 20% more than in a 
community. Therefore, long hospitalisation, risk conditions and oral consumption of 
food or drinks contaminated by C. difficile vegetative cells or spores, assist the 
colonisation of C. difficile in the bowel (Rupnik et al., 2009). 
 
The fight to prevent nosocomial infection-associated diarrhoea has soared in the 
healthcare societies during the last decades, as it costs various governments billions 
of dollars. The United States spends about $3.2 billion yearly on the investigation, 
hospitalisation, and treatment of C. difficile-associated diarrhoea (CDAD) (O’Brien, 
2007); the United Kingdom spent about £200 million on CDAD in 2005 (Blondeau, 
2009). Therefore, studying the epidemiology and pathogenicity provides an overview 
of epidemics and should help to reduce health care osts. 
 
In 2002, the European Study Group for C. difficile (ESGCD) studied the CDI rates in 
212 European hospitals, and indicated that the mean incidence of CDI in European 
countries was 11 cases per 10,000 admissions. However, in 2005, there was progress 
in the health care service; the statistics indicated the prevalence being 0.13 to 7.1 
cases per 10,000 patients per day. Although between Oct. 2003 and Jun. 2004, the 
largest outbreak of hypervirulent epidemic ribotype 027 in the United Kingdom was 
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present in Stoke Mandeville Hospital in Buckinghamshire. During this epidemic, 
nineteen patients died, and was followed by another outbreak in the period of Oct. 
2004 to Jun. 2005 by an equal mortality rate and the same type of C. difficile. The 
causes referred to the poorness in the health care facilities and the poor restriction of 
antibiotic use (Freeman et al., 2010). The incidence rates of C. difficile infection 
(CDI) change significantly depending on the diagnosi g facility, antibiotic 
consumption system, the application of infection cotr l, and overall hygiene (HPS 
2011). 
 
Bauer et al. (2011) studied the incidence of CDI in Europe and the geographical 
allocation of C. difficile ribotypes in 34 European countries. They collected data 
from 106 laboratories to demonstrate the distribution of C. difficile in November 
2008, and showed the 014 PCR ribotypes as being the commonest in European 
investigation centres and 001 in 13 countries. However, the hypervirulent ribotype 
027 was ninth, and in regards to pervasiveness and multi-country surveillance. It is 
important to detect and manage CDI and to show variations between different 
countries (Table1.1). 
Country  Number of toxin 
positive cases/number 
of patients tested and 













Finland 52/351 (15%) 141 19 106 
U.K 164/1695 (10%) 115 43 106 
Ireland 38/493 (8%) 94 18 106 
Denmark 28/330 (8%) 74 16 023 
Sweden 69/430 (16%) 74 28 014 & 020 
Germany 93/602 (15%) 72 22 001 
 
Table1.1: The Data show the most common PCR-ribotypes er European country 
and number of patients tested per day as well as percentage of positive cases (taken 
from Bauer et al., 2011). 
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C. difficile strains have produce toxins: enterotoxin (A) TcdA and cytotoxin (B) 
TcdB, which are responsible for the diarrhoea (Starr, 2005). Subsequently, the 
severity of CDI symptoms is related to the production of these toxins, and some 
strains also produce binary toxin (CDT) (Akerlund et al., 2006; Bouvet and Opoff, 
2008).  
 
The amino acid sequences for toxins A and B are similar for about two thirds of their 
structure. The enterotoxin and cytotoxin are effectiv  in C. difficile pathogenicity; 
and the action of these toxins includes binding to several receptors on the epithelial 
cell surfaces and membranes with enzymatic activity on cytoskeleton formation, as 
well as the discharging of several pro-inflammatory cytokines from the colonic cells, 
macrophages and mast cells (Rupnik et al., 2009).  
 
The hypervirulent ribotype 027, which produces a high level of toxins A and B, 
appears to have the highest severity and mortality r te (Dupuy et al., 2008).  
 
Fortunately, there is a suggestion that insufficient toxin receptors on the epithelial 
cells in infants could prevent the host from symptomatic colonisation and other 
factors associated with the resistance of virulent C. difficile colonisation. This is 
because the epithelial toxin binding doesn’t happen all over the intestine of neonates 
(Kaslow and Shiver, 2011).  
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Furthermore, the hypervirulent ribotype 027 is not the predominant strain in 
Scotland; the dominant strains change from time to time, and place to place 
depending on several factors. It has recently been studied in Scotland that the most 
frequent strains are 001 ribotype and 106 ribotype (HPS reports 2011; Freeman et al., 
2010).  
 
However, there is still a compromised community risk; all populations are threatened 
by CDI as a result of changes in epidemiology and the antibiotic susceptibility of 
new strains of C. difficile (Kuntz et al., 2011).  
 
During the last decade, the distribution of C. difficile has altered in Scotland. Taori et 
al., (2010) investigated the period 1979-2004 for the pr dominant ribotypes of C. 
difficile in southern Scotland and the changes in antibiotic susceptibility, The study 
indicated that the most frequent ribotypes were 002and the incidence during the 
study period for 001 ribotype increased eight times which reflected the highest 
antibiotic resistance pattern, while 012 ribotype decrease from 8.7 to 2%. 95.5% of 
the total isolates were resistant to clindamycin but there is no resistant isolates for 
vancomycin in their study. However about 18% of isolates are resistant to two 
antibiotics and fewer than 8% were resistant to three or more antibiotics. 
 
Also, the Wiuff et al., (2011) study indicates that ribotypes 106 and 001 have been 
the dominant strains in Scotland for the years 2008 and 2009. It also shows that more 
than 93% of C. difficile dominant ribotype isolates show resistance to clindamycin, 
erythromycin, levofloxacin, moxifloxacin and cefotaxime, as they can be declared as 
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multidrug-resistant strains. In addition, low doses of antibiotics amplifying the ability 
of resistant strains are the main cause of change i C. difficile epidemiology and 
antibiotic susceptibility, as suggested. Thus, one f the effective ways to avoid 
hypervirulent strains is through control of antibiotics, which requires a prospective 
epidemiological study, and antimicrobial susceptibili y (Shears et al., 2010).  
 
An uncontrolled CDI outbreak is caused by several factors; these factors are related 
to the patient conditions, hospital facilities, health care systems, microbe ribotypes, 
and the microbiota disturbance (Goorhuis et al., 2011). 
 
The host association factors are divided into two groups: host health conditions, such 
as haematological malignancy, inflammatory bowel disease, and geriatric, or other 
compromisation factors (Harbatrth et al., 2001). The second group concerns the 
medical process and treatments, such as nasogastric intubations, acid suppression, 
proton-pump inhibitor, H-2 receptor antagonist, corti steroids, long-term 
hospitalisation, and high exposure to broad-spectrum antibiotics, such as clindamycin 
and third generation cephalosporin, as well the oral antibiotic consumption 
contributing to disturbing the gut microbiota, (Starr et al., 2003). 
 
The exposure of C. difficile to ampicillin and clindamycin may stimulate some 
binding factors, such as SLPs, Fbp68 and Cwp66, and enzymatic activity, such as 
cysteine proteases Cwp84, which corrupts bowel epith lium (Dene`ve et al., 2008).  
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Additionally, prophylaxis from low doses of first generation cephalosporins or the 
use of new generation fluoroquinolones are associated with the lack of control of a 
CDI outbreak and resistance of the hypervirulent ribotype 027 ( Pepin et al., 2005). 
 
However, there are some antibiotics that have a low risk, such as aminoglycosides 
and tigecyline; the latter is a member of the glycylcycline antibiotics and which have 
a wide spectrum effect on anaerobic bacteria, which causes the toxin production of 
C. difficile to be dormant (Baines et al., 2006). 
 
Rupnik et al. (2009) claim that the controlled use of third generation, broad-spectrum 
antibiotics could reduces the CDI infection up to 90%. As well the application of 
infection control regulations, such as hand washing, patient isolation, using 
disposable equipment, striving for the surveillance of CDI, and regular teaching 
programmes for healthcare employees, is recommended by Starr (2005).  
 
Additional to the antibiotics-used factors associated with the CDI, some viral 
infections also contribute. Wilcox and Fawley (2007) noticed that the CDI rate was 
higher in the wards infected by norovirus gastroenteritis. There were also factors 
affecting colonisation, such as gene expression stimulated by some intestinal stressed 
circumstances, like hyperosmolarity (Dene`ve et al., 2008). 
 
Moreover, the weakness of the infection control system in health care organisations 
as well as the poor diagnostic tools for the control of CDI outbreaks assist the 
epidemic (Morrison et al., 2011). Furthermore, some aspects of C. difficile ribotypes, 
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such as toxin production and genes encoding multi-resistance, have an effect on the 
virulence of CDI and distribution of types. At the same time, some of the previous 
factors are related to community-acquired infections a d others to the nosocomial 
infection (Goorhuis et al., 2011).  
 
Patients who are suspected as having CDI were the persons developing diarrhoea in 
the community or the hospital following consumption f antibiotics. These were 
accompanied by any debilitating condition or any health risk factors, such as when 
the liquid stool is sometimes bloody, combined with general signs, like fever, the 
loss of appetite, nausea and abdominal pain, as well as a rising white blood cell count 
in about 40% of CDI patients and a decrease in blood albumin in more than two 
thirds of infected persons (Knoop et al., 1993).  
 
The symptom of vomiting and a typical serial gap in the outbreaks distinguish 
antibiotic-associated diarrhoea by C. difficile from that caused by norovirus and other 
bacterial infections, as well laxative abuses or other inflammatory gut illnesses. The 
incubation period of CDI is usually two to ten weeks after the start of antibiotic 
consumption, to when symptoms appear (Cheng et al., 2011).  
 
1.2 C. difficile Typing: 
 
Most members of the genus Clostridium are motile, and there are variations in 
oxygen tolerance, but C. difficile is typical of the genus being Gram-positive, rod-
 10 
shaped, with subterminal spores and are strictly anaerobic and produce exotoxins, 
which are the main reasons for pathogenicity. 
 
The categorisation of pandemic C. difficile isolates depends on accurate typing 
methods and of detecting the relatedness between C. difficile strains in the outbreaks. 
There have been many techniques developed for typing and these included the 
detection of phenotypic markers or a genotypic markers, which has become a 
universal technique to detect epidemics, as it is quick, easy, and suitably 
discriminative (Indra et al., 2008; Bidet et al., 2000).  
 
One of the genotypic techniques is the polymerase chain reaction (PCR) ribotyping, 
which is based on the presence of a number of alleles of the rRNA operon, with 
variation in the length of the intergenic spacer region. This involves the amplification 
of the targeted fragments of rRNA between the 16S and 23S genes during several 
rounds of amplification in a thermocycler to create easily detected amounts of rRNA 
by using the two primers in the16S and 23S flanking re ions (O’Neill et al 1995; 
Bidet et al., 2000; Singh et al., 2006). Moreover, Indra et al. (2008) claim that there 
are more than 250 ribotypes; the minority of them are human pathogens. 
 
Analysis of PCR ribotype is traditionally based on electrophoresis in agarose gel and 
has been confirmed as being a useful tool for the epidemiological analysis of C. 
difficile outbreaks in European countries as it is easy to use and is low-cost, 
comparatively. However, the main defect in this assay i  the weakness of resolution 
of fragment size analysis and difficulty in comparing patterns between labs.  
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On the other hand, Indra et al., (2008) assert that fluorescence dye labelling on the 
16S primer for amplification of fragments and they developed the technique which 
they named capillary gel electrophoresis ribotyping, which is abbreviated as "sr". 
This new technique was developed to decrease considerably the time required for 
this test if a capillary sequencer was available in the laboratory. Furthermore, web-
based software permitted sharing the data between analysis centres in order to 
conquer the problems related to contrast typing of C. difficile isolates, such as 
standardised chemicals, methods and tools. 
 
The patterns used in the PCR capillary gel electrophoresis ribotyping are the 
different sizes of inter-gene spacer regions of the rRNA gene of the microorganisms, 
and the extent of these areas in C. difficile ranges from 233-680 bp. This feature 
makes PCR more sensitive, as it is able to distinguish C. difficile subgroups. For 
example, the capillary gel electrophoresis ribotyping differentiates seven subgroups 
from the 014 ribotype, as studied by Indra et l., (2008). 
1.3 C. difficile pathogenicity: 
 
Bacterial pathogenicity is mainly related to the prsence of gene-encoded virulence 
factors. However, most of the CDI in a human takes place during or after antibiotic 
consumption; also, compromised patients, like the eld rly, are able to be colonised 
by C. difficile, and it is possible to isolate C. difficile from neonatal faeces as these 
are carriers without symptoms (Poxton et al., 2001).  
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Adult patients colonised by C. difficile were able to be converted to infections when 
the gut microbiota was disturbed by medication or there were changes in health 
conditions (Hogenauer et al., 1988). Therefore, the colonisation of the bowel starts 
by orally consuming C. difficile vegetative cells or more likely spores, followed by a 
disturbance of colonic microbiota by medication or h st predisposing factors, which 
makes the colonic epithelial cells susceptible to being attacked by infectious agents, 
with varying severity of infection (Rupnik et al., 2009; Fagan et al., 2009).  
 
Then, the vegetative C. difficile cells adhere to the colonic epithelial cells by 
different factors, such as hydrolytic enzymes, putative capsules, and surface-layer 
proteins (SLPs) and flagella proteins (Tasteyre et al., 2001; Dingle et al., 2011). 
However, most of the effective factors in the pathogenicity are toxins A and B, 
which degrade the actin cytoskeleton of the human intestinal cells and kill epithelial 
cells. These diminish the gut barrier function and consequently cause fluid to 
accumulate. Furthermore, these factors stimulate thhost immune system; 
inflammation presents and produces a pseudomembrane. Fi ally, the diarrhoea, 
colitis and toxic megacolon are the result and are oft n life-threatening (Rupnik et 





Figure 1.1: The diagram designed by Rupnik et al., (2009) reviews and illustrates the 
infection procedure. TcdA= Toxin A, and TcdB= Toxin B. Blue cells = neutrophils 
 
There are three toxins produced by C. difficile - Toxin A, Toxin B and binary toxin. 
The first two toxins are coded on a pathogenicity locus, as in figure 1.3a. Toxin A 
(molecular weight 308 kDa and encoded by tcdA) is sometimes referred to as the 
enterotoxin according to the effect of gathering fluid in the intestinal loop model by 
raising exchange fluids in the epithelial cells, inhibiting built-up proteins, enhancing 
the making of prostaglandins as well as leukotriene, and breaking through the 
intestinal border with necrosis of the mucus membrane. Subsequently, blood plasma 
is secreted into the intestine. Toxin B (molecular weight 269 kDa and encoded by 
tcdB) has a cytotoxic action on cell lines and is often r ferred to as the cytotoxin 
reviewed by Rupnik et al. (2009).  
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As well both toxins are shared in two thirds of amino acid sequencing; they have 
binding activity to the epithelial cell wall and mebrane. Also, there is an enzymatic 
achievement on the cytoskeleton binding layer as well as on macrophage and mast 
cells (Cohen et al., 2010). 
 
Both of these toxins are single protein chains and have three functional areas; a 
binding domain on the C-terminal by β- solenoid structure, cysteine protease activity 
in the central part, which separates the glucosyl transferase domain (N-terminal) 
(figures1.2, 1.3) (Rupnik et al., 2009). 
 
Figure 1.2: The diagram shows the genes encoding TcdA and TcdB. In total there are 
five genes (tcdR, tcdB, tcdE, tcdA and tcdC) and are located on the pathogenicity 
locus (PaLoc) (Taken from Rupnik et al., 2009). 
 
Moreover, the enzymatic cleavage action is the commn activity in both toxins, 
which are cytotoxic for cell lines in vitro, while the effectiveness of toxin B is higher 
by 100-1000 times more than toxin A. After damaging the intestinal epithelial cells, 
this is followed by the formation pf pseudomembranes as a result of degrading the 
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actin cytoskeleton, then stimulating the host immune system to produce tumour 
necrotic factor-α (TNF-α) and interleukins (ILs) (Darkoh et al., 2011).  
 
 
Figure1.3: The structure and functions of toxins A and B, where the catalytic and 
binding domains are peripheral and the translocation d main is central and contains 
the hydrophobic region. The enzymatic activity and substrate specificity are on the 
N-terminal (reviewed by Rupnik et al., 2009). 
 
The C- terminal of toxin A, which binds with host cells, is composed of a five part 
recurring structure consisting of glycopeptides. This part may stimulate the infection 
by an enterotoxin effect, while toxin B (tcdB) consist  of 18 cell wall-binding parts, 
and has cytotoxic action. These features are used in a standard diagnosis of CDI are 
cytotoxicity and toxigenic assays (Crobach et al., 2009; Cohen et al., 2010). 
 
The binary toxin is produced by some strains. However, there is no good evidence 
for its function in the colonisation of human bowel epithelial cells or for causing cell 
damage during infection (Bouvet and Opoff, 2008). The binary toxin or CDT is 
encoded on another part of the chromosome (CdtLoc) and includes three genes (cdtR, 
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cdtA and cdtB), the two unlinked proteins are CdtB and CdtA, but CdtB is a binding 










Figure 1.4: This diagram illustrates the structure and functions of the binary toxin 
(Taken from Rupnik et al., 2009). 
 
Additional to toxin A and B, binary toxin is suggest d as being a virulence factors in 
C. difficile. It is known as actin-specific ADP-ribosyltransferase toxin or CDT. The 
CDT was investigated by western blotting, while TcdA and TcdB genes for toxins A 
and B were examined by PCR. To date, the role of the CDT in C. difficile 
pathogenicity has not been confirmed in human CDI, but it is known to induce 
microtubule formation in tissue culture cells and may aid adhesion of C. difficile 
cells in vivo (Schwan et al., 2009).  
 
Although TcdB and TcdA are predominant in the pathogenicity of C. difficile, other 
factors also support these toxins in the infectious process. The competition 
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phenomenum between bowel microbiota indicates the contribution of intestinal 
colonisation by non-toxic C. difficile, and that other commensal microbiota protect 
the host bowel from CDI as a symbiotic relationship; therefore, disturbances of 
microbiota by the antibiotic use enhance C. difficile (Sambol et al., 2002). 
 
Dingle et al. (2011) suggest that the surface layer proteins (SLPs) havea role in the 
adherence step in the infection process, since the cell wall proteins (CWPs) fasten 
SLPs on the external cell surfaces of C. difficile, and SWPs 66 and SWPs 84 are 
concerned with adhering to epithelial cells and may d mage outer cell matrices. 
Furthermore, the flagellar proteins of C. difficile (FliC, FliD) and the basic structure 
of flagella are a part of the connection process to or penetration of the mucus layer in 
the epithelial cells.  
 
The capsule is suggested as being a virulence factor in bacterial infection and an anti-
phagocytic part by Tasteyre et al. (2000). 
 
1.4 The relationship between intestinal defence system and microbiota: 
 
The intestine is one of the highest sites of microbial colonisation in the human body, 
and the relationship between microorganisms and the gut indicate efficiency of the 
host defence, which is characterised by differentiati g between pathogenic and non-
pathogenic microbes; some of these microorganisms are commensal and the other 
pathogens are opportunistic (Schiffrin and Donnet-Hughes, 2011).  
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The function and structure of the intestine allows the bowel to control the microbiota, 
where digesting food, removing undigested food and pathogenic agents, are some of 
intestinal functions. Moreover, regulating the mucus membrane, intercellular linkage, 
epithelial cells and immune responses are other functions (Kim and Ho, 2010). 
 
There are four types of luminal epithelial cells: absorptive enterocytes, goblet cells, 
Paneth cells and enteroendocrine cells. The goblet cell range from 4% to 16% in a 
colon and depend on the rising microbial count. Goblet cells secrete some 
components of mucus, such as mucins, peptides, and binding proteins. The mucins 
have roles in human innate and adaptive immunity - for instance, the effect on 
binding with pathogens, adhesion, growth factors, and cytokines (Dharmani et al., 
2009).  
 
The major cells are enterocytes, which are absorptive and also responsible for 
producing cytokines and chemokines in order to control immune cells in the 
subordinate tissue; the Paneth cells create antimicrobial peptides, and 
enteroendocrine cells generate peptide hormones. Furthermore, the lymphoid cells 
activate indigenous particles which are provided to immune cells in the lymph nodes. 
Although the ability of the cells involved in innate immunity to identify antigens of 
pathogens in the bowel depends on imperfect feature receptors, which cannot specify 
the antigens when exposed, they can generally distinguish pathogen-associated 
molecular patterns and are useful in the organising the adaptive immune response 
(Schiffrin and Donnet-Hughes, 2011). 
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The innate immune system has many actions, such as a chemical barrier, like acidity, 
in the stomach and the intestinal folds with movements, such as physical action; also, 
pepsin, trypsin and other enzymes, bile and microbiota competition have a role in 
inhibiting infectious agents, and phagocytes and antibodies attack foreign bodies 
(Janeway et al., 2001). 
 
One of the first lines of protection from foreign bodies in the host bowel is epithelial 
cells, which sense the pathogens and unusual growth of indigenous microorganisms 
and promote the immune system. The mucus layer protects he epithelial cells from 
physical and chemical injury and prevents the cells from direct contact with 
endogenous antigens. 
 
 Immunoglobulin A (IgA), which is bound to the mucus layer and which prevents the 
attack of pathogens in the  gut lumen by neutralising bacterial lipoproteins, whilst 
also combining with many antimicrobial peptides, which are secreted by Paneth cells 
that have a function in preventing the intestine lumen from microbial attack. These 
compounds have an influence on defences such as lysozyme and cathelicidins 
(Maldonado and McCormick, 2011).  
 
As the main role in the gut homeostasis is influenced by mucosal antibodies, 
Benckert et al. (2011) suggested that the disproportion in the IgA and IgG production 
by B cels in the intestine may be accompanied by bowel diseases. However, they 
found that a quarter of intestinal IgA and IgG were polyreactive. Mainly, specific 
detection of the pathogenic and commensal microbes as well self-antigens and 100% 
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of the bowel antibodies were somatically modified, which clarified that colonic 
homeostasis is the result of specific immune B cellresponses in the intestine; this 
provides essential recognition of uncontrolled defence reactions present in 
inflammatory gut diseases.  
 
Therefore, many microorganisms have modified their invasion methods to avoid 
these barriers, such as C. difficile toxins, which weaken the stability of a tight 
junctional complex (TJC), such as claudins and occludins, which prevent bacterial 
adherence to epithelial cells and which control epithelial cell permeability (Nusrat et 
al., 2001). 
 
Identification of pathogens and molecular structures related to microorganisms, like 
flagellin, peptidoglycan, and lipopolysaccharide (LPS), also formylated peptides in 
lumen cells, is done by receptors, such as the extracellular Toll-like receptors (TLRs) 
and the intracellular Nod-like receptors. These receptors induce IL-1, IL-6 and 
tumour necrosis factor alpha (TNF-α) as part of the innate immune system. In 
addition, there are huge families of cytosolic pattern recognition receptors, which 
also have subfamilies that depend on N-terminus patterns. All of these receptors are 
involved in surveillance of the extracellular, endolysosomal and cytoplasm signs in 
the infection and damaged epithelium layer (Kawai and Akira, 2006).  
 
Inflammation of innate immunity can be stimulated by antigens, which enhance the 
adaptive immune reaction by activating the antigens a d which achieve the desired 
stage via interaction with pattern recognition receptors (PRR). These molecules pass 
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the cell membrane into endosomal compartments inside the cell, and through a series 
of reactions, cytokines and chemokines are produced. Therefore, innate immunity 
has the “decision” on protection and bowel stability. For instance, in the 
steady/healthy bowel, the symbiotic microbiota enhance epithelial cells in order to 
produce homeostatic cytokines, uch as TGF-β, to suppress the dendritic cells (DC), 
which are required to create a primary antibody, while stimulating the pro-
inflammatory cytokine production through epithelial cells to stimulate the DC in the 
infection (Schiffrin and Donnet-Hughes, 2011).  
 
In addition to the competition of symbiotic microorganisms to the pathogens in the 
bowel, the microbiota are involved in gut homeostasi , the endorsement of intestinal 
lymphoid tissues and the amplifying production of intestinal villi also accompanies 
the life cycle reduction of epithelial cells. It also affects epithelial cell permeability, 
intestinal mucous layer composition, thickness, compactness as well as mucin 
formation (Maldonado-Contreras and McCormick, 2011). Moreover, the creation of 
some antimicrobial peptides by Paneth cells was considerably increased by the 
presence of bowel microbiota, as opposed to gut-free microorganisms (Karlsson et
al., 2008). 
 
Consequently, the intestinal innate immune system is a primary defence, which 
maintains a stable bowel microbiota and symbiotic microorganisms, which assist 
intestinal immunity, as well as presenting antigens to the adaptive immune system. 
Additionally, elucidating the pathogen-associated molecular pattern effects will 
clarify the pathogenicity and will control the infection. Furthermore, figure 1.5, 
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which was designed by Maldonado-Contreras and McCormick (2011), expresses the 
role of innate mucosal immunity by intestinal epithelial cell performances.  
 
Figure1.5: The intestinal epithelial cell properties that regulate innate mucosal 
immunity. The abbreviations are: antimicrobial peptides (AMPs), interleukins (IILs), 
immunoglobulin A (IgA), polymeric immunoglobulin A receptor (pIgAR), human 
cathelicidin (LL-37), lipopolysaccharide (LPS), M cells microfold cells, macrophage 
(Mø), mitogen-activated protein kinases (MAPK), adaptor proteins MYD88, TRIF, 
TIRAP, TRAM, Rip2, nuclear factor kappa-B (NF-κB), nucleotide-binding 
Oligomerization domain (NODN), pathogen-associated molecular patterns (PAMPs), 
toll-like receptors (TLR) (Reproduced from Maldonado-Contreras and McCormick, 
2011). 
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1.5 C. difficile cell wall structure:  
 
The cell wall structure of C. difficile consists of a cytoplasmic membrane from inside 
the peptidoglycan polymer layer, which is coated by the cell wall proteins and the 
lipoteichoic acid (lipocarbohydrate antigen LC) included in peptidoglycan (La Riva 
et al., 2011).  
 
Fagan et al. (2009) diagrammed the C. difficile cell wall and exemplified two 
molecular weights of surface layer proteins (SLPs), high molecular weight (HMW) 
and low molecular weight (LMW), as well as other small cell wall protein 
components (Figure1.6). These cell wall proteins may h ve roles in bacterial 
adhesion to epithelial cells (Calabi et al., 2002). 
 
 The other clostridial wall proteins (CWPs), which are enclosed to the three cell-
binding motifs, are in small amounts and have an encoded gene called cwp; most of 
them are supposed to have a role in adhesion, such as Cwp66, which is a phase 
variable protein, CwpV, Cwp84 and Cwp2, which is a cysteine protease (La Riva et 
al., 2011).  
 
Additional to CWPs, C. difficile genomes determine a number of putative surface 
proteins which have been distinguished at the molecular level, for example, fbp68 
encoding a fibronectin binding protein (Fagan et al., 2011). 
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Figure 1.6: Model of the cell wall of C. difficile. The diagram illustrates two SLP 
peptidoglycan layers: the HMW SLP (light grey) and the LMW SLP (dark grey). The 
white structure indicates other small cell wall proteins (taken from Fagan et al., 
2009).  
 
La Riva et al. (2011) simplified the role of some CWPs in the structure of a cell wall. 
Firstly, the preprotein production includes a signal peptide. The second step is 
removing Cwp84 and Cwp13 preproteins, and by autocatalysis activity in Cwp13, 
the activity is not cleared in Cwp84 when combining Cwp13 to structure the 
enzymes, which is included in the S-layer. Next, high and low mol. wt. SLPs is 
formed after the SlpA primer form cleavage by active Cwp84. Finally, the Cwp13 
identified the mis-folded proteins and arranged its at achment in the growth medium 
of the bacterial cell wall (figure 1.7). 
 
Figure 1.7: Represent the processing and activities of Cwp84 and Cwp13 proteins. 
(S-L, S-layer; PG, peptidoglycan; Mem, membrane; Cyt, c toplasm). Taken from La 
Riva et al (2011). 
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The second layer in the clostridial cell wall is peptidoglycan PG, which is located 
between the cytoplasm membrane and CWPs and is 80 nanometres thick; the 
teichoic acids are part of it. Despite poor knowledg  of PG structure and biosynthesis 
in C. difficile, it seems to contain a high amount of glycan, which is more than 90% N-
deacetylated; the non-acetylated amino sugars offerresistance to lysozyme. Also, the PG 
biosynthesis in C. difficile was suppressed by some antibiotics, which may be a 
hypothetical key in the infection control by antibiotics (Peltier et al., 2011; Fagan et al., 
2011).  
 
The Peltier et al., (2011) study of composition and structure of C. difficile PG show 
the homologous proteins in C. difficile genome contain ldtcd1 (CD2963), ldtcd2 
(CD2713) and CD3007. It is supposed that these proteins contain a transmembrane 
area which has catalytic activity with the SXGC conserved motif in different levels 
and the other protein in C. difficile genome which has no hydrophobic areas that 
could act as binding membrane but contain a putative peptidoglycan anchor area 
consisting of three CWB-2 modules or two SH3 modules. The sequence of preserved 





Figure 1.8: The diagram shows the chain of preserved motifs, and L, as well as the 
D-transpeptidase domain composition of C. difficile peptidoglycan and the identity of 
the catalytic area. The grey terminal is the strap area and the black is the catalytic 
part; both are supposed peptidoglycan. The Ldtcd1 that encodes a protein of 469 
residues and Ldtcd2  (CD2713) and CD3007 display significant sequence identity with 
the Ldtfm catalytic domain, also all of them have no hydrophobic regions (Peltier et 
al., 2011). 
 
1.6  C. difficile antigens: 
 
The pathogenicity of C. difficile is related to many components, such as toxins A, B
and binary. Also, cell wall-, flagellar- and surface-associated proteins are suspected 
to be involved in the infection. These compounds are mainly induced in an 
immunological reaction between host and microorganisms (Sanchez-Hurtado et al., 
2008; Fagan et al., 2011; Spigaglia et al., 2011). Although the majority of C. difficile 
isolates from patients produce one or more toxins, some previous studies claim that 
the C. difficile virulence is related only to Toxin B. However, recently, many 
researchers have suggested that the infection is associ ted to two toxins 
(Permpoonpattana et al., 2011). 
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The cell wall and flagella proteins are a part of the outer surface of bacterial cells, 
which have direct contact with epithelial cells. These proteins consist of SLPs and 
CWPs. Up to now, the predominant proteins in the C. difficile cell wall are the 
surface layer proteins, which are composed of two parts of high and low molecular 
weight surface layer proteins (HMW and LMW) SLPs (Fagan et al., 2011; Spigaglia 
et al., 2011).  
 
The C-terminal proteins are the base of HMW SLPs, which are responsible for 
mediating attachment to the underlying cell wall byputative cell wall binding 
motives (Pfam), and the LMW SLP is the immunogenic region which contains the 
N-terminal proteins (Spigaglia et al., 2011). 
 
 In fact, it is recognised by specific antibodies from sera of patients infected by C.
difficile, and the specific immunoglobulin for some of these proteins is present in 
CDI cases. However, the different versions of CwpV may assist C. difficile to escape 
from our innate defences. Moreover, a C. difficile congregation in the bowel that is 
encouraged by CwpV might affect the colonisation; the CwpV role in infection needs 
more investigation (Spigaglia et al., 2011; Reynolds et al., 2011).  
 
The hypotheses of SLP roles in bacterial adhesion, which is suggested by Calabi et 
al. (2002) according to their in-vitro and in-vivo adhesive observations, as well as the 
immune response investigation to SLPs by Sanchez-Hurtado et al. (2008) and Wright 
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et al. (2008) recommended that the SLPs have a role in bowel colonisation and are a 
helper factor in C. difficile infection and antigenic active proteins.    
 
The C. difficile flagellar proteins FliC and FliD and the surface-associated protein 
Cwp66 and Cwp84 roles in the infection were revealed by Pechine et al. (2005), 
when they detected immune responses to these proteins after CDI. 
 
1.7 The immune response to C. difficile:  
 
1.7.1 General view of immunity: 
 
The host differentiates between self and non-self entiti s by different methods. The 
immune system is divided into two parts, the innate and adaptive immunity. Innate, 
or natural immunity is the first line of defence as well as it being characterised by 
being fixed in the genome, non-clonal, with immediate ctivation and recognising 
conserved molecular patterns, like lipopolysaccharide (LPS), lipoteichoic acid 
(LTA), mannans, and glycans. Also, it responds to co-stimulatory molecules, such as 
cytokines (IL-1β, IL-6) and chemokines (IL-8). The effector cells consist of 
macrophages, polymorphonuclear leukocytes, and mastcell , which were created by 
innate immune detection. While one of the effective natural intestinal barriers is 
microbiota, normal colon movements and the acidity in the gastrointestinal tract 
protect the bowel from C. difficile colonisation. These phenomena led us to think 
about a probiotic strategy with non-toxic CD, which prevents hamsters from CDI 
(Poxton et al., 2001; Janeway and Medzhitov, 2002; Sambol et a ., 2002). 
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The gut immune system is activated when neutrophils are stimulated by IL-1, IL8, 
TNF-α and leukotriene B4, which are produced by stimulating resident cells by the 
antigens. The neutrophils migrate from blood vessels to colonic mucosa in a massive 
way. The specific antagonistic peptide controls thiinflammation and this peptide is 
present in gut tissue (Poxton et al., 2001).  
 
The innate immune mechanisms detect and destroy infect ous agents without a 
prolonged period for induction; it also discriminates between host cells and pathogen 
cell surface. However, adaptive immunity needs more stages to remove infectious 
material, beginning with transporting antigens to lymphocytes then a recognition 
phase after the clonal expansion and differentiation  effector cells. Finally, it 
removes the infectious agents, but is characterised a  specific with memory to control 
reinfection (Janeway et al., 2001).  
 
The adaptive immune system is encoded by clonal genes, is concerned with the 
details of molecular structure, and specifically identifies proteins, carbohydrates, 
lipids, nucleic acids and whole pathogens. The two parts of the immune system use 
the same effecter cells (Janeway and Medzhitov, 2002). As the gut mucosal tissue is 
the main mediator for pathogenic access for the host, the adaptive immune cells 
secrete huge quantities of immunoglobulin (Ig) and the majority is an IgA antibody, 
which is one of the frontline defences to protect the epithelia. It passes between cells, 
translocating onto mucosal cells and is a part of the homeostasis in the bowel. Also, 
IgA in humans has two subclasses: IgA1 and IgA2. The IgA2 is more resistant to 
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bacterial proteases and is present in overloaded bacteri l growth areas. A second 
immunoglobulin detected in the lumen is IgE, and is involved in hypersensitivity 
reactions (Cerutti et al., 2011).  
 
Depending on the structure, cytokines are divided into three families: 1) 
Hematopoietin comprises growth hormones and some interleukins, such as IL-6; 2) 
Tumour necrosis factor TNF-α, and 3) Chemokines which are a division of 
cytokines. All cytokines have roles in both innate nd adaptive immunity, as the 
cytokines are produced when the bacterial products stimulate macrophage (Janeway 
et al., 2001). 
 
C. difficile antigens can be divided into two groups - toxins ad non-toxins. The 
toxins includes toxin A, B and binary, while non-toxin antigen includes SLPs, FliC, 
FliD, and surface-associated proteins, such as Cwp66 and Cwp84 (Sanchez-Hurtado 
et al., 2008; Kelly & Kyne 2011).  
 
Some studies on the inhibition of the severe reactions n colon epithelial cells caused 
by C. difficile toxins A and B show protection to epithelial injuries. Many studies 
indicate that more than 50% of a population have obvious levels of IgG and IgA 
antibodies to C. difficile toxin A and toxin B. Also, vigorous anti-toxic immune 
responses are present in the toxinogenic C. difficile carrier without symptoms, as 
opposed to symptomatic patients (Kelly & Kyne, 2011). 
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1.7.2 Functional role of surface layer proteins (SLPs): 
 
The SLPs have two components: high molecular weight (HMW) and low molecular 
weight (LMW). These proteins are created after a translational split of a precursor. 
SLPs are present in all C. difficile strains and the cell wall may have a role in 
adhesion to epithelial cells. Also, it is an immunodominant antigen by disturbing the 
cytokine equilibrium in human monocytes, and it stimulates monocytes to produce 
IL-10 and IL-12. Thus, the hypothesis of SLP effects on irritation of intestinal lining 
bowels is expected. So, Bianco et al., (2011) proposed that SLPs have similar 
immunomodulatory action. However, there is no variation between SLPs from 
hypervirulent and epidemic strains.  
 
McCoubrey and Poxton (2001) suggested that the SLPs, which show dissimilarities 
in isolated antigens, and their molecular weights, ave a role in immune reactions 
and bacterial virulence. Immunoblotting of SLPs canbe used to distinguish between 
isolates.  
 
The LMW SLPs are suspected as being an immunodominant antigen in C. difficile 
isolates by Spigaglia et al., (2011), as they notice that three specific peptids from 
the two exposed surface regions out of ten regions recognised PCR sequencing for 
LMW SLP between 027 ribotype and 001 ribotype. The thr e peptides predicted by 
human and rabbit anti SLPs for ribotype 027 and against SLPs from ribotype 001 in 
human sera only, which is supposed to be present in pathogenic bacteria. 
Consequently, it is significantly interesting to study the proposition of SLP 
effectiveness on epithelial cell activation and pathogenicity (Bianco et al., 2011). 
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Fibronectin binding proteins (Fbps) and the gene is FbpA 
Various cell surface receptors are responsible for the adhesion of pathogenic agents; 
these include fibronectin, fibrinogen, collagen and vitronectin. The SLPs were linked 
to collagen, thrombospondin and vitronectin, whereas fibronectin-binding proteins 
Fbps were suspected to join to fibronectin or laminin. Fibronectin is a glycoprotein 
present in the body fluids and in the extracellular component of human tissue; the 
Fbp in C. difficile is Fbp68, which has a weight of 68 kDa (Hennequin et al., 2003). 
 
1.7.3 Functional role of Flagellin:  
 
Although C. difficile toxin activity is the most important virulence mechanism in 
CDI, there is a hypothesis that flagella are involved pathogenicity features, such as 
virulence, adherence, invasiveness and colonisation, are suggested by Tasteyre et al. 
(2000).  
 
The flagellum structure shows a whip shape and it is responsible for bacterial 
movement. It consists of a single component polymer called flagellin. It is composed 
of about 500 amino acids polymerised to make up the flag llum, which is fixed to the 
cell wall by a base and hook. In addition, the flagella genes consist of three classes: 
transcriptional regulatory proteins (FliC/FliD) class, basal body and hook proteins 
(FliA/FlgM) (activator and repressor) class, and the ird class is genes encoding the 
hook filament adaptors, cap, motor, chemosensory system, and the flagellin protein 
that polymerises to form the flagellar filaments (Aderem et al., 2009). 
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Tasteyre et al. (2001) confirmed the function of encoded genes FliC (fliC 39-kDa) 
and encoded genes FliD (fliD 56-kDa) and flagellar proteins in the adherence to the 
luminal cells in vitro; they provide colonisation, as they recognised the flagellar C. 
difficile strains had adhered to mouse caecum tissue ten times higher than non-
flagellar strains.  
 
The function of the flagellin polypeptide is suspected to encourage the essential 
immune response by stimulating the Toll-like receptors as well as inducing several 
cytokines, thus enhancing the adaptive immunity. The activation of the immune 
system demolishes the foreign body and prevents infection in the gastrointestinal 
system (Aderem et al., 2009). 
 
1.7.4 Functional role of Lipocarbohydrate LC: 
 
The majority of Gram-positive bacteria cell membranes consist of peptidoglycan-
attached carbohydrate-based polymers into their cell casing, such as cell-wall 
glycopolymers and these polymers are involved in the protectiveness of bacterial 
cells, gut epithelial cell adhesion, irritation and have immunogenicity activity 
(Weidenmaier and Peschel, 2008). 
 
C. difficile cell envelope consists of a cytoplasmic membrane, SLPs and between 
them, the peptidoglycan, which includes lipoteichoi acid (LTA) (lipocarbohydrate 
LC antigen) (Sharp and Poxton 1985; La Riva et l., 2011), and the antigenic activity 
of C. difficile LC, which was extracted by aqueous phenol and EDTA, was 
investigated by Sanchez-Hurtado et al., (2008) to IgG and IgM responses, which 
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shows a high level to both immunoglobulins. However, they did not notice 
significant differences in the antibody levels betwen the control and the study case 
groups.  
 
Mohamadzadeh et al. (2011) deny that the lipoteichoic acid enhances th  dendritic 
cells (DCs) to produce proinflammatory cytokines (e.g., IL-12) that are causative of 
ulcerative colitis and Crohn’s disease in humans, and that removing the 
phosphoglycerol transferase gene, which plays a key role in the lipoteichoic acid 
biosynthesis in Lactobacillus acidophilus, one of the normal gut components, down-
regulates IL-12 levels and considerably alleviates induced dextran sulphate sodium 
(DSS) in mice; thus gene changes of  normal gut bacteri l flora, such as 
Lactobacillus acidophilus, may propose alternative therapy if immune responses ar  
regulated. 
 
1.7.5 Functional role of Capsule:  
Davies and Borriello (1990) proposed that toxigenic isolates of C. difficile may have 
other potential factors, such as capsules, flagella and hydrolytic enzymes, and that 
the anti-phagocyte activity in vivo may be affected by capsules, as its location is in
the bacterial cells. However, little more has been reported on capsules in C. difficile 
and it is uncertain whether they exist. 
 
1.8 C. difficile antibiotic susceptibility: 
 
Treatment CDI with antibiotic not include asymptomatic carriers as well oral 
antibiotic consumption disturbs the gut microbiota and enhances C. difficile to 
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colonise the bowel as well as to invade the epithelial cells in order to establish the 
infection complications, and it can take at least twenty days or more up to months for 
the human bowel to recover homeostasis (Bartlett et al., 1992; Poxton, 2010; Kee, 
2012).  
 
However, some antibiotics suppressed the C. difficile growth and the pathogenesis 
ability. The relationship between antibiotics and C. difficile is not clear with a wide 
range of effects, even to anaerobes.  For example clindamycin enhances C. difficile 
to colonise the host gut, while moxifloxacin does not. On the other hand, ampicillin 
does not have a broad spectrum or weak activity to anaerobic bacteria, thus 
distinguishing it as an associated antibiotic to CDI ( ene`ve et al., 2008; Pituch et 
al., 2011). 
 
Thus, discontinuing the present antibiotic in use is ssential in the CDI medication or 
at least should be replaced by safer antibiotics to av id diarrhoea which may cure 
25% of cases within 4-5 days, except for the cases cannot stop antibiotics, which 
brings about dehydration. Therefore, substitute electrolyte is required (Kee, 2012).  
 
The cheapest treatment choice is oral metronidazole, as opposed to the expensive 
vancomycin, (and it is essential for MRSA treatment). Furthermore, the normal 
intestinal peristaltic movement is essential to clean the gut from the pathogens, and 
anti-peristaltic agents often used to treat diarrhoea are not recommended for CDI, as 
it can interrupt the improvement also the exchange resins should avoid when treat 
CDI as it may combine with antibiotics (Poxton, 2010; Kee, 2012). 
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The standard treatment of metronidazole or vancomycin is 10 days, which supports 
reinstating the microbiota and stops chances of recur ing, as suggested by (Bartlett, 
1992). Even though vancomycin is expensive, it is suitable for the incompatible 
patients to metronidazole; the other disadvantages of metronidazole are decreasing 
the susceptibility to neurotoxic complications and may replace vancomycin by 
teicoplanin (Beloosesky et al., 2000; Brazier et al., 2001; Cheng et al., 2011). 
 
 Recently a narrow-spectrum macrocyclic antimicrobial fidaxomicin become as 
novel strong competitor to vancomycin as there is no variation of clinical cure rate 
between both antibiotics. Moreover fidaxomicin is more durable resolution of CDI 
and may be has lesser disturbances effect on bowel microbiota during treatment as 
well in the CDI infection by 027 ribotype, the record rate of recurrent infection is 
less, which is make fidaxomicin so far the safer antibiotics to treat the CDI as well 
fidaxomicin approved for adults from food and drug administration (FDA) as 
vancomycin (Poxton, 2010; Louie et al., 2011; Kee, 2012). 
 
1.9 Alternative treatments for CDI: 
 
Many non-antibiotic methods to control CDI have been approach such as passive and 
active immunization also probiotics are being investigated. Intravenous 
immunoglobulin (IVIG) as treatment for CDI has not been successful so far, but 
recently some studies investigated intravenous injection of monoclonal antibodies 
against toxin A and toxin B and these have shown acceptable results (Lowy et al., 
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2010). A newly developed vaccine by Sanofi Pasteur which is based on toxoid has 
been granted a fast-track development from the FDA in 2011 (Kee, 2012). 
 
A considerably effective probiotic organism in CDI treatment was Saccharomyces 
boulardii and has also been used to avoid or decrease diarrhoe  when using 
antibiotics. Other studies used Lactobacillus rhamnosus or a combination including 
bifidobacteria. However, some of these may cause bloodstream infections, and due 
the shortage of information especially for compromised patients, the Society for 
Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of 
America (IDSA) guidelines do not recommend probiotics to prevent primary CDI 
(Kee, 2012).     
 
1.10 CDI managing procedures: 
 
The most important precautions to avoid spread of C. difficile by visitors include 
recommending the use of gloves and gowns as well as hand washing with 
antimicrobial soap after patient contact (figure1.9) and to avoid alcohol-based hand 
sanitizers. Medical staff should provide a private commode for CDI patients if 
isolation rooms are not available and they should avoid reusable equipment which 
could be a source of C. difficile spores. Also, strict supervision should be made to 
restrict antibiotic use especially for cephalosporins, broad spectrum penicillin and 
clindamycin except for surgery prophylaxis advice. Cleaning areas where CDI 
patients are present should be done with sporicidal agents and chlorine (hypochlorite 




Figure1.9: Picture of hand washing steps from http://www.cvh.on.ca/patient-safety/  
 
To put it briefly, C. difficile is one of the superbugs which is terrifying the healthcare 
organisations. It colonises the human gut causing a range of symptoms from 
relatively mild watery diarrhoea to life-threatening pseudomembranous colitis and 
Fulminant colitis and toxic megacolon. Its spores are present in the community and 
the hospital environments, also it is resistant to many antibiotics (but not to those 
used for treatment) and the frequencies of their ribotypes and the antibiotic 
susceptibility are variable.  
 
 As the first step of infection is likely to be adhesion, the binding of the C. difficile 
outer cell wall components with the receptors of epithelial cells represents the 
adhesion stage. As well there are various bacterial outer cell wall compounds with 
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different immunogenic effect which are suspected to have different roles on the host 
immune response. Thus, studying the immune responses to these C. difficile cell wall 
structures and flagellar proteins by estimating the immunoglobulin level in the serum 
of symptomatic and non symptomatic patients as wellas normal healthy donors may 
clarify the distribution of the immune response against bacterial antigens in the 
different stages of infection. 
  
As well, the effects of bacterial antigen on the innate and adaptive immunity by 
exposing the antigens to the monocytic cells such as the THP-1 cell line to estimate 
the production of interleukins to induce the pathogenicity. This may allow the follow 
up of patients, to investigate CDI, to protect patients and to control the infection. 
 
On the other hand, predicting the changing of C. difficile ribotypes distribution and 
antibiotic susceptibility can help to avoid outbreaks and helps with the health care 
cost and makes life safer particularly for compromised patients. 
 
 
1.11 Aims of the thesis: 
 
There is wide debate about the activity of the cellwa l and flagellar proteins, such as 
their effectiveness in adhesion, gut colonisation and the immunogenic activity. It 
was, therefore, reasonable to study these features to understand the Clostridium 
difficile epidemiology, pathogenicity and the host immune response. Thus, the thesis 
contains five research topics: 
 40 
 
• To identify C. difficile isolates from surgical patients and their environme t 
by capillary gel electrophoresis to determine the distribution of C. difficile 
PCR ribotypes by this new technique and to distinguish the predominant 
ribotypes in the surgical unit, as well as to compare the results to agarose gel 
electrophoresis. 
 
• To estimate the antibiotic susceptibility in the strains isolated above to six 
antibiotics (ampicillin, erythromycin, tetracycline, metronidazole, 
moxifloxacin and vancomycin) and to detect the MICs for these six 
antibiotics against the C. difficile isolates.  
 
• To separate the cell protein SLPs, lipocarbohydrate (LC) and flagellar 
proteins from the six most frequent strains in the South Eastern area of 
Scotland, in order to determine the hypothesis of immunogenicity of these C. 
difficile proteins. 
 
• To evaluate the antibody (IgG) levels by ELISA in the healthy donor and 
hospital-admitted elderly patients from South Eastern area of Scotland to C. 
difficile SLPs, LC and flagellar proteins from the six most common ribotypes 
(001, 002, 0012, 0027, 078, 106)  as well as highly immunogenic LPS from 
E. coli as a control.. Hospital admitted patients were classified as 
symptomatic cases, asymptomatic patients (carriers) and non-colonized 
patients as controls, and this depends on the stages of C. difficile colonization.  
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• To determine the affects of different antigens on induction of chemokines and 

























































The chemicals used in this study were prepared by international standard methods, 
unless mentioned otherwise. The distilled water (Millipore, Billerica, MA, USA) 
used in all water base chemicals solution, except in PCR preparation where 
Nuclease-free water (NFW), was used. Phosphate buffered saline (PBS) was 
prepared in all research by dissolving ten tablets of PBS (Oxoid, Basingstoke, UK) in 
one litre of pyrogen-free water and autoclaved before use. All other autoclavable 
chemicals were autoclaved prior use. 
2.1 Samples investigated in the study: 
 
Blood, stool and environmental samples were used in the study analysis.  
 
2.1.1 Samples and ethics: 
 
The Local Research Ethics Committee approved all clinical sampling. Stool and 
blood samples were collected from surgical ward patients and their environment was 
also sampled – at the Western General Hospital (WGH), the Royal Victoria Hospital 
in Edinburgh. Serum samples were collected from theBlood Donor Centre 
Edinburgh. 
 
2.1.2 C. difficile isolates:  
 
The 140 C. difficile isolates used in this study were isolated from stool  from 
different patients and their environments in surgical wards of the WGH. These were 
collected by Dr Surekha Reddy, one of MPRL group memb rs. Control strains were 
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from the MPRL group culture collection.. All strains were stored in cooked meat 
broth and subcultured on blood agar or CCEY medium before picked for colonies for 
any proposes of the research. 
 
2.1.3 Blood samples: 
 
Blood samples consisted of 230 healthy donor samples and the patients samples 
included 20 samples from symptomatic patients, 20 samples from carriers as well 26 
control samples from the collection of MPRL group which are collected during 2006. 
 
2.1.3 Culture media:  
 
The following media used in the investigation were for different purposes: to store 
bacteria or determine colony characters and sometimes for distinguishing C. difficile. 
However the enrichment growth to produce the biomass and that for determination of 
MICs required special broth media. 
2.1.3.1 Blood Agar medium (BA):  
 
Blood agar medium used for bacterial growth and the ingredient are Proteose 
peptone 15g/L, Liver digest 2.5 g/L, yeast extract 5g/L, NaCl 5g/L and agar 12g/L , 
also  pH adjusted for 7.4 at 25°C. Horse blood was added to a final concentration of 
5% of medium. 
 
2.1.3.2 Cefoxitin-cycloserine-egg yolk agar (CCEY): 
 
This contained Proteose peptone No 2 (Difco) 40g, Na2HPO4 5g, KH2PO4 5g, NaCl 
2g, fructose 6g, MgSO4 .7H2 O 0,2g, Neutral red (1% neutral red in ethanol) 3ml and 
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Agar (Bacteriological agar, Oxoid L11) 20g, after autoclaving added sterile Egg yolk 
(Oxoid SR047C) 50ml, cefoxitin (1.6g/l) 5ml and D-cycloserine (50g/l) 5ml were 
added.  
 
The ingredients were dissolved in 1L distilled water and autoclaved at 121°C/15 
minutes then cooled to 50°C. The agar was dispensed in 15 to 17 ml amounts into 
9cm Petri-dishes and allows setting. To dry the surfaces of plates they were kept at 
37°C for about 1 hour, and then stored at 4°C (George et al., 1979). 
 
2.1.3.3 Protease Peptone Yeast Extract Medium (PPY medium): 
 
The PPY medium was used for an anaerobic growth of C. difficile strains. The 
ingredients consist of: Protease peptone (Oxoid) 20g; Yeast extracts (Oxoid) 10g, 
NaCl 5g; cysteine HCl (3.75% w/v solution) 20ml; sodium carbonate (2% w/v 
solution) 20ml; haemin (250µg/ml)/ menadione (50µg/ml) were added to 850ml 
distilled water. The pH was adjusted 7.1 and made up to 1 litre with distilled water. It 
was autoclaved at 121°C for 15min then stored at 4°C, or dispensed in 4ml in bijoux 
or 15ml to universals tube and autoclave at 121°C/15 minutes with caps loose. The 
caps were tighten caps when still hot, immediately on removal from the autoclave, 





2.1.3.4 Cooked meat broth:  
 
Cooked meat media used to store the C. difficile at room temperature. The contents 
of the medium were Proteose peptone (Oxoid L85) 20g, Yeast extract (Oxoid L21) 
5g, Trypticase (BBL 11921) 5g, NaCl 5g, cysteine HCl (3.75% aqueous solution) 
20ml (or 750mg dry), Na2CO3 (2% aqueous solution) 20ml (or 400mg dry) and 20ml 
Haemin + menadione solution. 
 
The ingredients were dissolved in 940 ml distilled water then the pH adjusted to 7.1 
and the volume completed to 1L. It was dispensed 4ml in bijoux and added 0.5cm 
dry cooked meat particles or 15ml plus 1cm dry cooked meat particles to universals, 
or as required, and autoclaved at 121°C/15 minutes after that recapping whilst still 
hot and store at 4°C. It was pre-reduced at or 37°C for 24h in the anaerobic cabinet 
before use. (Practical Medical Microbiology, 14th edition, p507 -511) 
 
2.1.4 Chemicals:  
 
The chemical required in epidemiological study include Gram stain and ribotyping 
reagents.  
2.1.4.1 Gram stain reagents: 
 
0.5% w/v aqueous methyl violet, 2% iodine in 0.1M NaOH, acetone and 0.1% 
aqueous basic fuchsin were used in Gram stain. 
 
2.1.4.2 Chemicals for ribotyping: 
 
The ribotyping methodology followed that of O'Neill et al., (1996) with the 
modification of Indra et al., (2008) for capillary gel electrophoresis (CGE).  
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Utilizing the oligonucleotide primers complementary to the 3' end of the 16S rRNA 
gene in the positions 1445-1466 and the 5' end of the 23S rRNA gene in the position 
1-20 which was labelled by florescent dye carboxy-fluorescein (FAM), the variable 
length intergenic spacer region was amplified. Prime s were obtain from MWG and 
the sequences of the primers were: 
 
16S 5’ CTG GGG TGA AGT CGT AAC AAG G3' 
23S 5’ GCG CCC TTT GTA GCT TGA CC3'  
 
The master mix for 100 samples contained: nuclease-free water 251µl, bovine serum 
albumen (BSA 2mg/ml) 100 µl, PCR buffer (Promega flexi X5) 200 µl, dNTP mix 
(2mM) 100 µl, MgCl2 (25mM) 140 µl, primer 16S (100µM) 2 µl from MWG, primer 
23S (100µM) 2 µl from MWG and TAQ (5u/µl) 5µl from Promega.  
 
Diluted samples contained HiDi formamide 995 µl and LIZ-600 size markers 5 µl. 
Three PCR tubes per plate were required for capillary gel electrophoresis. The final 
volume of the PCR reaction for each sample was 8 µl + 2 µl DNA extraction. 
 
Firstly, denaturation was done at 95 °C for 5min, and then 25 cycles in 1min at 95 °C 
for the denaturation of the mixture were carried out. And then annealing at 55°C for 
1min was processed, followed by extension at 72°C for 90 sec. The last step was 
elongation for 5min at 72°C. 
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The amplification product (1 µl) was diluted ten times in Nuclease-free water 9µl, 
then mixed by pipette, 1µl transferred to another PCR-microplate tube which 
contained 9µl of diluent sample and covered by aluminiu  foil. The PCR-microplate 
was then centrifuged at 112g for 2min (the diluted amplified product could be stored 
at 4°C until reading by sequencer). The patterns were identified by contrast with 
control ribotypes from the library collection.  
 
2.1.5 Identification methods: 
 
C. difficile was identified by colony morphology characteristics and appearance 
under long-wave UV light. Microscopy was used to confirm bacterial cell shape by 
Gram-staining reaction and motility was checked in 24-48h old cultures following 
strict anaerobic growth.   
 
2.1.5.1 Colony characters:  
 
To identify C. difficile colonies morphology was used on CCEY agar or blood agar, 
and exposure to long-wave UV light to reveal the characteristic yellowish-green 
fluorescence.  
 
2.1.5.2 Gram stains Procedure: 
 
The bacterial film was prepared and heat-fixed. Thefilm was flooded with methyl 
violet and left for one minute. After a brief rinse in tap water, it was flooded with 
iodine and left for 1 minute. After rinsing with tap water, it was decolourised briefly 
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(for 2 - 3 seconds) in acetone and then promptly washed well in tap water. The last 
stain was basic fuchsin and was left for one minute. Finally, it was rinse briefly in tap 
water and blotted dry. Gram positive and Gram negative bacterial strains were used 
as control. 
2.1.5.3 Motility investigation: 
 
Hanging-drop techniques was used to differentiate th bacterial motility and 
investigated by dark field background microscope. 
 
 
2.1.6 Anaerobic work station: 
The anaerobic workstation (MK3, DW Scientific, Shipley, Yorkshire) was used to 
provide anaerobic condition via hydrogen 10%, nitrogen gas 80% and carbon dioxide 
10%. 
 
2.1.7 Ribotyping techniques: 
 
The principle of PCR ribotyping for C. difficile is rooted in the intergenic spacer 
sections of 16S-23S ribosomal RNA gene which is extremely heterogeneous with 
many alleles also the size of the space between allles vary between different strains. 
 
Multiple copies of the different sized spacer regions of the C. difficile genome were 
amplified, by the Polymerase Chain Reaction (PCR) (Stubbs, 1999). The products 
can be differentiated by their banding patterns on agarose gels, or, as here, one of the 
primers (5`) was labelled with FAM to allow the products to be analysed by capillary 
gel electrophoresis, and a DNA sequence reader. Final analysis was done by Gene 
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Marker software V 1.95 and the patterns were matched by eye to the ribotype library 
developed by this technique.  
 
2.1.7.1 Specimen preparation and DNA extraction: 
 
A few colonies from fresh cultures of C. difficile isolates and controls grown an 
anaerobically for <48 hrs at 37°C on blood agar were collected. They were 
emulsified in 100µl of Chelex suspension (0.05g/1ml NFW) (Chelex 100 resin Bio-
Rad) in Eppendorf tube, then heated for 10-15 minutes in a boiling water bath or 
heat-block to lyse the bacteria.  
 
The suspensions were next centrifuged for 10min for 14000g, and then 40 µl of the 
supernatant was transferred to another sterile empty tube by sterile tip. The DNA 




The C. difficile ribotype mastermix preparation was made as in table 1. The 
mastermix was stored at -20°C until required in 400µl aliquots and protected from 
light. This was stable at least one year.  
 
Components Stock concentration ×100 samples 
Nucleases-free water (NFW) ------ 251 µl 
Bovine serum albumin (BSA) 2mg/ml 100 µl 
PCR buffer (Promega flex) ×5 200 µl 
dNTP mix 2mM 100 µl 
MgCl2 25mM 140 µl 
Primer 16S FAM (MWG) 100µM 2 µl 
Primer 23 3S (MWG) 100µM 2 µl 
TAQ (GoTaq) 5U/ µl 5 µl 




Sample diluents buffer consisted of: 
Components ×100 samples 
HiDi formamide 995µl 
LIZ-600 size markers 5 µl 
 
Samples diluents buffer were mixed well and frozen at -20°C in 500 µl aliquots and 
protected from light. They remained stable for one year but were discarded after 
thawing. 
 
PCR amplification protocol: 
The previous prepared C. difficile ribotype mastermix was thawed from -20°C 
storage in 37°C water bath and placed in ice immediat ly as well as avoiding direct 
light. An 8 µl volume of mastermix was distributed to a suitable number of PCR 
tubes on ice, and cover by dome caps. A 2 µl volume of specimen DNA extraction 
was added, as well relevant controls to the wells. The PCR tubes were place in the 
thermocycler. 
Thermocycler CDIFF protocol was: 
Temperature Time Cycles 
95 °C 5min 1× 
95 °C 60sec 
55 °C 60sec 
72 °C 90sec 
 
25× 
72 °C 5min 1× 
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The PCR product after amplification could be storage t -20°C before processing by 
fluorescent fragment analysis and should be kept in the dark. 
 
2.1.7.3 Fluorescent fragment analysis: 
 
Samples for fluorescent fragment analysis were prepared as follows: 
A 9 µl volume of NFW per sample was dispensed into a 96-well PCR plate (A), and 
9 µl of sample dilution buffer per sample was dispensed into plate B and discarded of 
any amount of sample buffer not used.  
 
1 µl of each PCR product was dispensed into the wells in plate A and mixed 
thoroughly to make 1/10 dilution of PCR products in water, and 1 µl of each diluted 
sample was transferred into the matching well in plate B which contained HiDi 
formamide, so the final dilution will be 1/100.  
 
The plate was covered carefully using adhesive foil seal and mixed carefully by the 
vortex mixer. Finally the sample sheet was completed for the capillary sequencing 
process in the GenePool laboratory in the Ashworth Building at the King’s 
Buildings, University of Edinburgh.   
2.1.7.4 Reading of capillary electrophoresis sequences results:  
 




2.2 Antibiotic susceptibility:  
 
Minimum Inhibitory Concentration (MIC) determination followed the agar plate 
diffusion CLSI (2007) methods. 
 
2.2.1 Bacterial isolate:  
 
A panel of 140 C. difficile isolates from surgical patients and their environme t at the 
Western General Hospital in Edinburgh UK, and the control strains from MPRL 
group at the Centre for Infectious Disease at the University of Edinburgh. 
 
Five separate colonies (diameter~1mm) of C. difficile isolates were selected from the 
growth on supplemented Brucella horse blood agar which ad been incubated in 
anaerobic conditions for 24-48 hrs. The colonies were suspended in brain-heart 
infusion (BHI) broth and the turbidity adjusted to an O.D. 0.5 at 625nm (BSAC 
methods for antimicrobial susceptibility testing V 10.2 May 2011). 
2.2.2 Antibiotics: 
 
The NCCLS methods was followed for antimicrobial susceptibility testing of 
anaerobic bacteria approved standard – seventh edition (M11-A5 Vol.21 No.2) Hecht 
et al (2007). In the MIC technique for this study, the direct colony suspension 
method was chosen, and six antibiotics were used (ampicillin, erythromycin, 
tetracycline, metronidazole, moxifloxacin and vancomycin).  
 
For each concentration, 1ml horse blood + 2ml antimicrobial agent solution were 
added to the plate and 17 ml cooled Supplemented Brucella Agar, poured into it and 
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mixed gently and left covered to cool at room temperature. Plates were used within 
72 hours.  A multi-point inculcator was used to inoculate the strains. 
 
Pouring Agar dilution:  
Serial dilution of antibiotics were prepare as in Table 2: 
Steps Concentration Source Volume Diluents Conc. µg/ml Log2 Final Conc.(g/l) 
 5120 µg / ML Stock ___ ___ 5120 9 512 
1 512 Stock 2ml 2ml 2560 8 256 
2 512 Stock 1ml 3ml 1280 7 128 
3 512 Stock 1ml 7ml 640 6 64 
4 640 Stock 2ml 5ml 320 5 32 
5 640 Stock 1ml 3ml 160 4 16 
6 640 Stock 1ml 7ml 80 3 8 
7 80 Stock 2ml 2ml 40 2 4 
8 80 Stock 1ml 3ml 20 1 2 
9 80 Stock 1ml 7ml 10 0 1 
10 10 Stock 2ml 2ml 5 -1 0.5 
11 10 Stock 1ml 3ml 2.5 -2 0.25 
12 10 Stock 1ml 7ml 1.25 -3 0.125 
 
Table2: Serial dilution of the antibiotics 
 
2.2.3 Media used in MICs: 
 
2.2.3.1 Brain Heart Infusion broth (BHI: Oxoid): 
 
The BHI broth used to prepare the C. difficile suspension in the MIC determination, 
contained brain infusion 12.5g/L, beef hearts infusion 5g/L, glucose 20g/L, NaCl 
5g/L and sodium phosphate 2.5g/L. 
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2.2.3.2 Brucella Agar Medium (B.A.)( Sigma): 
 
Brucella Agar Medium used in MIC determination for C. difficile after adding horse 
blood (5%), the components were casein 19g/L, peptic digest 10g/L, yeast extract 




2.2.4.1 Chemicals for MIC: 
 
The MIC for C. difficile isolates requires Brucella agar with horse blood, and the 
antibiotics with solvent. Also the brain heart infusion broth used for bacterial 
suspension and sterile PBS to dilute the bacterial suspension for the optical density 
evaluation by spectrophotometer. 
 
Six antibiotics were used in this study: ampicillin, erythromycin, tetracycline, 
moxifloxacin, metronidazole and vancomycin by different dilutions table 3.  
 
Antibiotic ampicillin erythromycin tetracycline moxifloxacin metronidazole vancomycin 
Potency ≥845 µg per mg ≥850 µg/mg 993µg/mg ~1,000µg/mg ≥900 µg / mg ~1,000 µg/mg 
Stock solvent NFW Ethanol 100% NFW NFW 0.1% acetic acid NFW 
 
Table 3: The potency and stock solvent used in antibiotic preparations.  
NFW = nuclease-free water. 
 
2.2.5 MICs procedure: 
 
Colonies of strains of C. difficile from BA plates grown for 48 h were inoculated into 
tubes of BHI broth and incubated anaerobically for 24 hrs.  The optical density of the 
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bacterial suspensions was read in a spectrophotometer at a wave length of 600 nm 
and the turbidity adjusted to 0.5 O.D. by addition of sterile PBS. Using a 36 well tile 
for the multi-inculcator the suspensions of different strains were inoculated onto agar 
plates contains different antibiotic concentration.  
 
The plates were incubated anaerobically, with one plate without inoculation as 
control and one plate aerobically as control for facultative anaerobic bacterial 
contamination. After 24 h the antibiotic susceptibili y was checked.  
 
2.3 Extraction of C. difficile antigens: 
 
2.3.1 Chemicals: 
2.3.1.1 Chemicals for S-layer proteins Extraction: 
 
Cell washing buffer: 0.05 M sodium phosphate buffer pH 7.4, containing 0.15 M 
sodium chloride. 
1.482g NaH2PO4.2H2O and 5.749g Na2HPO4 were dissolved in about 900ml distilled 
water and pH checked that it was 7.4. 8.77g NaCl was added, and when dissolved, 
made volume up to 1000ml with distilled water. 
 
5M guanidine HCl:  
 
9.553g guanidine hydrochloride was dissolved in about 10ml distilled water and then 
made up to a total of 20ml with distilled water. 
Dialysis buffer:  6.25mM Tris/ HCl buffer, pH 6.8. 
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757mg Tris (hydroxymethyl) methylamine was dissolved in about 950ml distilled 
water. The pH was adjusted to 6.8 using 1M HCl and then made up to a total of 
1000ml with distilled water. 
 
PPY Medium: Medium was mentioned previously in (2.1.3.3). 
Micro-dialysis membrane: Using a 10000 mwco membrane (Medicell international 
Ltd). 
2.3.1.2 Chemicals for Flagella protein Extraction: 
 
Phosphate buffered saline (PBS), Protease Peptone Yeast Extract Medium PPY 
Medium and Micro-dialyser 10 000 mwco membrane. 
2.3.1.3 Chemicals for Lipocarbohydrate (lipoteichoic acid: LC) extraction: 
 
Phosphate buffered saline (PBS), PPY broth, and chloroform/methanol solution (2:1) 
to delipidated the sample. Aqueous phenol solution 80% (w/w) and acetic acid/ 
acetate buffer (pH 5.0) containing 0.02 M MgCl2 and 100µg each RNase and DNase 
(Sigma) and toluene, as well Micro-dialyser a 10000 mwco membrane using. 
 
2.3.1.4 Chemicals for Polyacrylamide gel electrophoresis (PAGE):  
PAGE used to determine the purity of proteins. 
 
40% w/v aqueous acrylamide/methylene bisacrylamide solution:  
Add 100g acrylamide (BDH Electran) to 2.7g methylene bisacrylamide (BDH 
Electran) completed by nuclease-free water to 250ml. 
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Freshly prepared 15g/l w/v ammonium persulphate solution (APS):  
0.05% w/v aqueous bromophenol blue solution:  
 
Water saturated butan-2-ol  
About 60 ml butan-2-ol was added to a 100ml screw-capped bottle with 10ml 
nuclease-free water and shaken thoroughly after about 1 min and was checked to see 
if the solution was biphasic. If not, more water was added and mixed and rechecked 
until the solution was biphasic. 
 
Sample buffer (Single strength): 0.0625 M Tris/HCl; pH 6.8, 2% SDS, 10% glycerol, 
1% 2-mercaptoethanol and 0.001% bromophenol blue. 
 
0.757g Tris (hydroxymethyl) methylamine (BDH analar) was dissolved in 70ml 
water and adjusted to pH 6.8 with 1 MHCl then add 2g sodium lauryl sulphate 
(SDS) (BDH especially pure).  
 
12.6g glycerol (BDH analar) was accurately weighed directly into a 100ml 
volumetric flask and the bromophenol blue added. The ris/HCl/SDS solution was 
transferred to the volumetric flask and washed in wth several small volumes of 
water. In a fume cupboard, add 2ml mercaptoethanol (0.05% aqueous solution) 
(BDH water soluble) and made up to 100ml with water. It was mixed thoroughly and 
then 5 - 6ml volumes transferred to disposable bijoux wrapped in foil  
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Sample buffer (Double strength) 0.125 M Tris/HCl pH 6.8, 4% SDS, 20% glycerol, 
2% 2-mercaptoethanol, and 0.002% bromophenol blue:  
1.514g Tris (hydroxymethyl) methylamine (BDH analar) was dissolved in 60ml 
water and adjusted to pH 6.8 with 1 M HCl. 4g Sodium lauryl sulphate (SDS) (BDH 
especially pure) was added  25.2g glycerol (BDH analar) (20% v/v glycerol) was 
accurately weighed directly into a 100ml volumetric flask and 2ml bromophenol  
blue (BDH) added. The Tris/HCl/SDS solution was transferred to a volumetric flask 
and washed in with several small volumes of water. 
 
 In a fume cupboard, the 2-mercaptoethanol was added and made up to 100ml with 
water. It was mixed thoroughly and then 5 - 6ml volumes transferred to disposable 
bijoux wrapped in foil  
 
Electrode buffer: (0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3):  
 
6.057g Tris (hydroxymethyl) methylamine (BDH analar) nd 28.827g glycine (BDH 
chromatographically homogeneous) ware dissolved in1800ml water and the pH 
check to be 8.3. Minor adjustments can be made using 1 M NaOH (but not HCl). 2g 
sodium lauryl sulphate (SDS) (BDH especially pure) was added and made up to 
2000ml.  
 
Separating gel buffer (Double strength) (0.75 M Tris /HCl pH 8.8, 0.2% SDS): 
90.855g Tris (hydroxymethyl) methylamine (BDH analar) was dissolved in 800ml 
water and adjusted, initially with 5 M, and then 1 M HCl to pH 8.8. 2g sodium lauryl 
 60 
sulphate (SDS) (BDH especially pure) was added and ma e up to 1000 ml with 
water.  
 
Stacking gel buffer (double strength) (0.25 M Tris /HCl pH 6.8, 0.2% SDS):  
15.142g Tris (hydroxymethyl) methylamine (BDH analar) was dissolved in about 
400ml water and adjusted, initially with 5 M, and then 1 M HCl to pH 6.8. 1g sodium 
lauryl sulphate (SDS) (BDH especially pure) was added and made up to 500ml with 
water.  
 
TEMED: N, N, N, N- Tetramethylethylenediamine from (Sigma)  
 
2.3.2 Extraction methods for SLPs: 
2.3.2.1 C. difficile growth: 
 
20ml of PPY medium tube was inculcated and incubated naerobically overnight at 
37°C. The purity was then checked with a microscope. 
 
2.3.2.2 Cell wall separation: 
 
The cells were harvested and washed twice in cell washing buffer (10ml per wash) 
by centrifugation at 4800g for 15 mins, then the supernatants were discarded. Next 
the cells were resuspended in 1.5ml of 5M guanidine HCl in a 3ml tube, and mixed 
in an RBC mixer for two hours. After that, the cells were removed using an 
ultracentrifuge at 16,000g for two minutes, the supernatants collected and 
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centrifuged again at 16,000g for two mins. The cellfr e supernatants were carefully 
transferred to a clean tube. 
 
2.3.2.3 Dialysis:  
 
The supernatant was dialysed by a 10,000 MWCO membrane, against a 1 litre 
dialysis buffer at 4°C overnight. Protein was used to concentrate the solution, freeze-
drying it if necessary and storing at -20°C. 
 
2.3.3.4 Purification of SLPs: 
 
To check the purification poly-acrylamide gel, electrophoresis was used (PAGE) as 
described in Section 2.3.6. 
   
2.3.4 Extraction methods for flagellar proteins: 
 
2.3.4.1 C. difficile growth: 
 
The C. difficile strains were grown anaerobically overnight in 1 litre of PPY medium. 
 
2.3.4.2 Separate of flagellar proteins: 
 
The bacterial suspension was centrifuged at 13,000g for 10 mins at 4°C and 
supernatants were discarded. The bacterial sediment was resuspended in 20ml of 
PBS and a vortex for 2 mins in a blender at high speed. It was then centrifuged at 
12,000g for 10 mins, or 5,000g for 30 mins at 4°C. The supernatant was collected 
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and centrifuged at 12,000g for 10 mins at 4°C. Again, the supernatant was collected 
and centrifuged at 25,000g for 1 hour at 4°C. The sediment (flagellar proteins) was 
collected and resuspended in 1ml of PBS. 
 
2.3.5 Extraction methods for Lipocarbohydrate (LC): 
 
This method is based on Poxton and Cartmill’s (1982) and Sharp and Poxton’s 
(1986) procedure. 
 
2.3.5.1 C. difficile growth: 
 
Six litres of PPY broth were inculcated by the C. difficile strain and incubated 
anaerobically overnight at 37°C. 
 
2.3.5.2 Separate cell wall for LC: 
 
Harvesting of the cells was done by ultracentrifuge at 10,000g for 10 mins at 4°C. 
Then the cells were resuspended in 10ml of PBS and washed twice by centrifugation 
for two mins at 10,000g and 4°C. The PBS cell suspen ion was sonicated in ice by 
MSE Soniprobe for three mins at 10µm. To remove the cell walls and unbroken 
cells, the suspension was ultracentrifuged at 4000g for 10 mins at 4°C, followed by 
35,000g for 30mins at 4°C. The supernatant was freeze-dried overnight in a weighed 
container, then delipidated twice with 200ml of chloroform/methanol (2:1) solution 
overnight, and filtered through Whatman No. 1 paper and allowed to dry. The dry 
delipidated cell wall contents and membrane fraction were resuspended in distilled 
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water to 10% (w/v) and mixed with an equal volume of 80% (w/w) phenol solution. 
The mixture was stirred at room temperature for half an hour then centrifuged at 




The supernatant was dialysed by a 10,000 MWCO membrane against tap water 
overnight to remove the phenol.  
 
The dialysed material was then mixed with an equal volume of 0.2 M acetic 
acid/acetate buffer (pH 5.0), containing 0.02M Mg Cl2 and approximately 100µg 
each of RNase and DNase (Sigma), and incubated overnight at 37°C with the surface 
covered by toluene. 
 
2.3.5.4 Purification of LC and storage: 
 
The phenol extraction was repeated to remove nucleases, then dialysis repeated 
overnight against tap water of the upper layer. Next it was freeze-dried overnight in a 
weighed container, so the crude membrane antigen could be collected and stored at 
room temperature. 
 
2.3.6 Polyacrylamide gel electrophoresis (PAGE): 
 




2.3.6.1 Sample Preparation: 
 
The samples and double-strength sample buffer were thawed before working, and 
then equal volumes of sample were mixed with buffer (15µl of each) in a sealed 
eppendorf tube. Next it was boiled in a heat-block r boiling water bath.  
 
2.3.6.2 Gel Preparation: 
 
The slide and cover were properly cleaned and dried before use, then the slide was 
fixed with the cover in the cassette. The separating a d stacking gels were prepared 
as described in Table 4. 
 
 The separating gel was injected into the space between the slide and cover just 0.5ml 
lower than the edge. The separating gel was gently covered with 50µl of water 
saturated butan-2-ol and left for 5-10 mins to polymerise. Then the rest of the water 
saturated butan-2-ol was removed. A sufficient quantity of stacking gel was added 
and the comb was fixed to make wells in the stacking gel, before leaving it for 
polymerisation. 
 
Ingredient Separating gel 12% Stacking gel 4% 
Acrylamide solution (40%) 3ml 0.5ml 
Separating gel buffer (DS) 2.5ml ------------- 
Stacking gel buffer (DS) ------------ 1.25ml 
10% SDS 100µl 50µl 
Distilled water 4.35ml 3.2ml 
10% APS 100µl 50µl 
TEMED 10µl 5µl 
 
Table 4: The contents of the separating and stacking gels are enough to prepare two slides. 
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2.3.6.3 Gel Running: 
 
PAGE electrode buffer was poured into the tank (Bio-Rad) and the slide containing 
the gel was inserted (note that the surface of the buffer should cover the slide gel). 
The slide wells face the back (to the middle of thec amber), and the comb was 
removed and checked to ensure there were no bubbles. 10µl of prepared samples 
were dispensed and marker ladders were demonstrated in he gel wells using narrow 
tips and the sample sequence mentioned. (Note that bubbles should be avoided when 
placing the samples). The tank was covered properly and the power supply 
connected. The voltage was adjusted to 80 volts and the time to two hours. Finally, 
notice was paid to when the dye reached the lower edge of the slide. 
 
2.3.7 Blue Stain for PAGE: 
 
The blue stain was used to determine the purification of S-layers proteins, flagellar 
proteins and lipocarbohydrate. Alcohol and acetic ac d were used as fixatives before 




2.4.1 Sandwich enzyme-linked immunosorbent assay ELISA procedure: 
 









96 microtiter plate wells were coated by investigated antigens with a 5µg/ml 
concentration in coating buffer, and control and blank wells were coated by antigen 





 The following day the wells were aspirated and washed four times with wash buffer 
(0.05% Tween20 in sterile PBS) by adding 400µl/well. They were then inverted 




The wells were blocked using 200µl of blocking buffer (1% Bovine serum albumin, 
BSA (Sigma) in sterile PBS) per well, then wrapped in aluminium foil and incubated 
for two hours at 37oC on a shaker. The wells were then aspirated and the washing 
step repeated as previously. 
 
Binding step: 
Diluted antigen samples of 1:200 in PBS-ST were added to duplicate “test” wells and 
a single antigen control well. Additionally, a well was diluted using the standard 
control serum and added to the appropriate “test” as well as the serum control wells. 
A serum buffer was added to the blank and antigen control wells, then the plate was 
wrapped in aluminium foil and incubated for 90 mins at 37oC on the shaker. It was 




The conjugate (Rabbit anti-horse IgG alkaline phospatase) 1 in 10,000 in PBS-TF 
was prepared and added to all wells, then incubated for 90 mins at 37oC on the 
shaker. It was then aspirated and the washing step repeated.  
 
Developing colour step: 
The new preparation of alkaline phosphatase substrate is essentially composed of 
Sigma 104-105 phosphatase tablets, (p-nitrophenyl phos hate 5mg/ml) in a substrate 
solvent. Two tablets in 10 ml per plate are required, and this solution was added to 
all wells. Then the plate was incubated for one hour at room temperature without 
cover or until the colour intensity of the control was considered sufficient.  
 
Well content Antigen Antigen diluents Serum Serum diluents Conjugate Substrate 
Blank (B) - + - + + + 
Antigen 
control(Ag) 
+ - - + + + 
Serum control (S) - + + - + + 
Test (T) + - + - + + 
 
Table 5: Summary of ELISA steps. 
 
Evaluation optical density step: 
 
The absorbance measurement of optical density for wells was applied by an auto-
micro plate reader (Anthos, 2001) at 405nm (reference 620nm). All values were 
counted as the means of duplicate measurements and compared to the standard curve. 
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2.4.2 Enzyme linked Immunosorbent Assay (ELISA) chemicals: 
 
The ELISA sandwich technique was required for at lest five solutions, detailed as 
follows:  
 
2.4.2.1 Antigen diluents: 
 
0.05 M sodium carbonate buffer pH 9.6, 0.02% w/v sodium azide: 
In preparation a 0.05 M sodium carbonate buffer (0.848g Na2, CO3 and 1.428g 
NaHCO3) was dissolved in 500ml of distilled water and checked to ensure the pH 
was 9.6. 100mg sodium azide was then added to the buff r. (Note that this should be 
dispensed in 100ml aliquots and stored at 4°C.) 
 
2.4.2.2 Antiserum and conjugate diluents: 
 
0.05 M sodium phosphate buffer at pH 7.4, 0.85% w/v sodium chloride, 0.05% w/v 
Tween 20 and 0.02% w/v sodium azide 
 
1.482g NaH2PO4.2H2O and 5.749g Na2HPO4 were dissolved in about 950ml of 
distilled water and checked to ensure the pH was 7.4. Then 8.5g NaCl, 0.5ml Tween 
20 and 200mg sodium azide were added (or 2ml of a 10% w/v solution of NaN3), and 
the final volume was made up to 1000ml with distilled water. 
 
2.4.2.3 Blocking solution: 
 
0.05 M sodium phosphate buffer at pH 7.4, 0.85% w/v sodium chloride, 0.05% w/v 
Tween 20, 0.02% w/v sodium azide and 2% teleostean g latine.  
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2g of teleostean gelatin was added to 100ml of antiserum diluents and stored at 4C. 
 
2.4.2.4 Substrate solvent (for alkaline phosphatase): 0.05 M sodium carbonate buffer 
at pH 9.8 and 1.0 mM magnesium chloride. 
  
Preparation of 0.2 M carbonate/bicarbonate buffer stock solutions  
1.167g Na2 CO3 and 1.176g NaHCO3 were dissolved in 500ml of distilled water and 
checked to ensure it was pH 9.8. 102mg MgCl2 6 H2O was added. 
 
2.4.2.5 ELISA wash buffer (single-strength wash buffer): 
 
A preparation was made of 2000ml of a 10 X concentrated solution without the 
sodium azide; this was dispensed in 380ml aliquots and sterilised by autoclaving at 
15psi/15 mins and stored at 4°C.  Note that sodium azide must not be autoclaved as it 
may react with copper or lead components inside autoclaves, creating explosive 
metal azide. 
10 X concentrated solution: 
Oxoid phosphate buffered saline tablets (BR14a), 144g NaCl and 3.6g KCl were 
dissolved in about 1800ml of distilled water. 10ml Tween 20 was added and the 
volume made up to 1900 with distilled water. The aliquots of 380ml were then 
autoclaved at 15psi/15 mins and stored at 4°C. (Note that the pH of the 10X solution 
was 7.0)  
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2.4.3 Estimated IgG level in donors and patients by ELISA:  
 
The detection of cytokines was followed by the ELISA technique, as described 
previously in Section 2.4.1. 
 
2.4.4 Detection interleukins and TNF-α by ELISA: 
 
 The detection of cytokines was followed by the ELISA technique, as described 
previously in Section 2.4.1. 
 
2.5 THP-1 cell line: 
 
THP-1 is a human acute monocytic leukaemia cell line separated from a human male 
at one year old (Tsuchiya et al., 1980). 
 
2.5.1 Source of cell line: 
 
The source of the THP-1 cell line is the European Collection of Animal Cell Cultures 
(ECACC, Salisbury, U.K.) ECACC No: 88081201, and was a kind gift from Mr 
Adel Alkadidi from Glasgow University. 
 
2.5.2 Essential chemicals:  
 
2.5.2.1 Chemicals for Cell Line: 
- Human acute monocytic leukemic cell line (THP-1). 
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- RPMI-1640 medium (Sigma), Fetal Calf Serum (FCS) (Sigma), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, HEPES (Gibco) and Penicillin 
Streptomycin PS (Gibco). 
- Glutamine 200mM (Sigma). The freezing medium for THP-1 cell line storage 
contained 3ml of sterile glycerol (Sigma), 7ml of FCS and Phorbol myristate 
acetate (PMA). 
 
2.5.3 Cell line media: 
 
2.5.3.1 RPMI 1640 medium (Sigma) used to grow the THP-1 cell line. 
 
2.5.3.2 4-(-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Gibco) as 
supplement to the RPMI 1640 medium for enrichments cell line. 
 
2.5.3.3 Fetal Calf Serum (FCS) from Oxoid was used as a supplement to the RPMI 
1640 medium for enrichments. 
 
2.5.3.4 (PSG) from Sigma: 
 
Penicillin and streptomycin were used to prevent the cell line from contamination. 
Supplements of 200nM Glutamine were also added.  
 
2.5.3.5 Phorbol myristate acetate (PMA): 
 
PMA was added to RPMI 1640 medium to enhance the adh sion of bacterial cell 
wall proteins to the THP-1 cell line. 
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2.5.3.6 Freezing medium for THP-1: 
 
The ingredients contain 100ml of a sterile nutrient broth (Oxoid CM1), filter-
sterilised heat inactivated (at 56°C for 30 minutes) FCS 10ml and sterile 20% 
aqueous glucose solution. The components were aseptically mixed and dispensed in 
a 2ml sterile tube, then incubated aerobically at 37°C for 24 hours. The tube cap was 
loosened then the mixture was anaerobically incubated for 48 hours to detect 
contamination. Next the cap was tightened again and the mixture stored at -20°C. 
(Reference: Practical Medical Microbiology, 14th edition, pp.126-127). 
 
 
2.5.4 Cell line growth: 
 
2.5.4.1 Preparing the cell line: 
 
Precautions: 
Wearing lab-coat and gloves are essential in tissue culture room, the reagents and 
media were immersed in warmed water bath for 20min and the Class II cabinet was 
cleaned by ethanol 70% and wiped by paper towel. The incubator was disinfected 
weekly with TrigenII virucidal disinfectant concentrate from MEDI CHEM UK 
(diluted 5ml/1000ml distilled watter), distilled water, ethanol 70% and Biocidal 
spray 
2.5.4.2 Activating the THP1 cell line:  
 
Frozen cells were transferred to a 25ml falcon tube and 5ml warmed RPMI 1624 
medium was added, then centifuged for 5min at 1000 g. The supernatant was then 
discarded in a discarding bottle. Next, 5ml of the m dium was added to the pellet and 
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the vial was gently shaken until the pellet detached. The cell suspension was 
transferred to a little flask and 5ml of medium adde . Finally the flask was incubated 
for 24-48 hours at 37°C in a cleaned incubator, and then the medium was changed 
after its colour changed to orange/yellow. 
 
2.5.4.3 Changing the medium: 
 
The medium was changed approximately every two days, depending on the colour 
developed about the cell line. The cell line was removed to the falcon tube and 
centrifuged for 5 min at 100g, after which the supernatant was discarded in the 
discarding bottle, and around 10ml of fresh warmed edium added to the cell pellet 
in the small flask, or 20ml to the large flask. 
 
2.5.4.4 THP-1 cell line procedure: 
 
To start with, the cell line was sub-cultured in 30ml of RPMI 1624 medium (Sigma) 
and 6ml of FCS with 3ml 100mM autoclaved 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid and (HEPES) (Gibco) (RPMI/20%FCS/HEPES), then 
incubated for 24-48 hours at 37°C. 
  
For routine growth, the cell line was sub-cultured in a mixture of 
RPMI/10%FCS/PS+G, which was prepared previously by adding 50ml of FCS, 5ml 




To discriminate cell growth a RPMI/PS+G mixture was added, which was arranged 
previously by adding 5ml of PSG to 500ml of RPMI medium. The cells were then 
stimulated by adding 2ml of 10ng (PMA) (Sigma) to 20ml of the cell suspension.  
 
The THP-1 cells were preserved by being grown in combination with RPMI. 
10%/FCS/PSG, which was prepared by adding 50ml of FCS and 5ml of PS+G to 
500ml of RPMI medium, and incubated for 24 hours at 37°C. The cell suspension 
was then transferred to a falcon tube and centrifuged for 5 mins at 100g. Next the 
THP-1 cells were added to 10ml of freezing medium containing 3ml of sterile 
glycerol (Sigma), and dispensed in 1ml tubes then stored in liquid nitrogen. 
 
2.5.4.5 Preparation of THP-1 cell line for bioassay: 
 
A confluence of cells (16×105 cells/ml) in RPMI/10%FCS was required. 
Untreated cells: 100µl of cells were added to each well of 96 well tissue culture 
plates and incubated at 37°C in  5% CO2 overnight. 
 
Pre-treated cells: 2ml (10ng/ml & 50ng/ml) of PMA was added to 20ml of cell 
suspension. Then 100µl of this suspension was distributed to each well of 96 well 
tissue culture plates and incubated for 24 hours at 37°C in 5% CO2. The medium 
was gently removed after centrifugation (100g for 5 mins) and replaced by serial 
dilution of SLPs, LC or flagellin. 
 
2.5.4.6 THP-1 cells viability: 
Estimation of cell viability was carried out by spinn ng one volume of cells at 100g 
for 5 mins, then mixing the same volume of trypan blue dye with the cell suspension, 
 75 
and immediately observing the cells under a microscope. The equation of viable cells 
= (No. of unstained cells / total No. of cells) × 100. The dual chamber 
haemocytometer slide was used to count the cells.  
2.6 Expose HTP-1 cell line to C. difficile antigens (SLPs, Flagellin and LC): 
 
2.6.1 Preparation of SLPs, LC and flagellin to expose THP-1 cell line: 
 
Six serial dilutions of antigens in RPMI/10%HS medium, from different strains 
(1=1000ng/ml, 2=100ng/ml, 3=10ng/ml, 4=1ng/ml, 5=0.1ng/ml, 6=0.01ng/ml) were 
used by thawing 10µl of stock (1mg/ml) and adding it to 990µl of medium, to 
achieve 10 µg/ml. 30µl was then added to 270µl of medium to reach 1µg/ml 
(=1000ng/ml), which constituted the starter dilution. 
 
In order to get 200ng/ml, 20µl of 10µg/ml was added to 980µl of the medium. To 
make 2000ng/ml (2µg/ml), 50µl of 10µg/ml was added to 250µl of medium. This 
constitutes the starter concentration of 2000ng, 200ng, 20ng, 0.2ng and 0.02ng. The 
same dilution was used for positive control and 2 wells for negative control. 
 
2.6.2 PMA (50ng/ml and 10ng/ml) cell line media preparation: 
 
PMA 50ng/ml = (0.5ml P.S. + 49.5ml RPMI +2.5µl PMA). 
PMA 10ng/ml = (1ml P.S. + 99ml RPMI + 1µl PMA). 
 
2.6.3 Exposure of THP-1 to C. difficile antigens: 
 
First the seeded wells of the microplate THP-1 cellline were prepared as described 
in Sections 2.5.4.6 and 2.6.2. The viability of thecells was checked as described in 
Section 2.5.4.7, then marked wells as antigens dilution will be used. Next, 100µl 
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diluted antigens were added to the marked wells as described in Section 2.6.1. Some 
wells were left without inculcation and blank as contr ls. Cell line microplate was 
inculcated and incubated at 37°C, 5% CO2 for 8 hours for interleukins and 4 hours 
for TNF-α. Finally, supernatants were collected to evaluate the cytokines level by 
ELISA.  
 
2.6.4 Preparation of primary, standard and secondary antibodies to detect 
cytokines: 
 
Antibodies were supplied from eBioscience and PeproTech companies as shown in 
Table 6 (with kind help from Dr. Prerna Vohra). The standard curve was achieved 
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Table 6: Preparation of primary antibodies, standard cytokines and secondary 
antibodies with their concentration is presented. 
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2.7 Statistical analysis: 
 
In this study Excel and Minitab were used for statiical analysis. The data were 
checked for normality and then contrasted with each other. An unpaired t-test was 
used for normal distribution data and R2 was performed in the linear relationship 


































CHAPTER III  DISTRIBIUTION AND DISSEMINATION OF  










3.1 Introduction:  
 
This chapter is an epidemiological study for the C. difficile infection (CDI) in the 
surgical department of Western General Hospital, Edinburgh. Samples collected 
from the patients and their environments have been used, along with the control 
isolated from the MPRL group collection have been used. 
 
C. difficile is recognised as the primary cause of infectious nosocomial diarrhoea in 
Europe, including the United Kingdom. The first known large UK outbreak of the 
hypervirulent, epidemic ribotype 027 happened in a Buckinghamshire hospital 
between October 2003 and June 2004, where 19 people died. This was followed by 
another outbreak between October 2004 and June 2005, with the same cause and a 
similar mortality level; a lack of patient care, infection control and isolation facilities 
cause the disaster (Freeman et al., 2010).  
 
As described in Chapter I, C. difficile spreads in many environments as it is spore-
forming and heat-resistant, as well as not being affected by many antiseptic  
detergents such as hand soap or alcohol, and having resistance to many antibiotics. 
Furthermore, it the spread is facilitated by the incidence of diarrhoea caused by and 
associated with the antibiotics used for treatment (Li  et al., 2011).  
 
Hospitals are an important reservoir of C. difficile spores; the spores have been 
isolated from hospital equipment such as linen, furnit e surfaces and lavatories 
(McCoubrey et al., 2003). It is present in about 40% of geriatric patients (Sydnor and 
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Perl, 2011), and the spores are the primary cause of infection in hospitals (Lin et al., 
2011). 
 
Categorisation of the endemic C. difficile strains requires the application of a good 
typing scheme. Previously, many different techniques have been used for typing C.
difficile during the course of outbreaks in hospitals. These include genotypic and 
phenotypic tests, the latter being serotyping, bacteriophage typing, whole cell protein 
profiles, 35S methionine-labelled protein patterns, antimicrobial resistance patterns 
and immunoblotting (Knoop et al., 1993). However, these techniques may have 
disadvantages, such as poor reproducibility, weakness with regards to discrimination 
and the need for special equipment not available in most laboratories (O'Neill et al., 
1996). The development of these methods has made it asier to identify 
microorganisms and follow cases up, as well as predicting outbreaks. 
 
PCR-ribotyping based on gel is one of the easiest and most discriminating techniques 
for typing strains, but it is difficult to compare patterns from different places as the 
technique uses agarose gel images (Figure 3.4). However, Indra et al. (2011) 
modified the PCR method by labelling the 16S primer with carboxy-fluorescein 
(FAM) dye, and the results are analysed by a sequencer to make the PCR more 
accurate at identifying ribotypes (Figure 3.3).  
 
The aim of the study was to isolate C. difficile strains from hospitalised patients’ 
samples and samples taken from hospital environments, as well to identify strains and 
use ribotyping to verify the distribution and dissemination of C. difficile ribotypes. 
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Comparisons are also made between capillary sequencing PCR and metaphor gel 
PCR. 
 
3.1.1 Isolation of C. difficile strains: 
 
To date C. difficile has been isolated in many countries around the world. North 
American and European countries faced a significant hallenge in the last decade, 
with CDAD threatening the lives of geriatric patients and other compromised 
individuals like pregnant women (Balassiano et al., 2012). Nowadays, warnings are 
sounding in some areas of South America, Asia and Australia as CDI has begun 
spreading through these countries (Cheng t al., 2011). It may be that the remaining 
countries which have not recorded CDI do not have healt care protocols that include, 
facilities to isolate and identify C. difficile.  
 
027/BI/NAP-1 was the main cause of CDAD in North America, and has been 
thought to be the cause of epidemics in Europe as well as Asian countries, such as 
Japan and Korea (Balassiano et al., 2012). However, Mutlu et al. (2007) reported that 
the most frequent ribotype is 001, whereas Taori et al. (2010) recounted that the 
predominant ribotype in Scotland is 002. Recently the Health Protection Scotland 
(HPS) Network in its second quarter report documented that 106 and 001 ribotypes 
had decreased compared to the previous years, and 027 was now uncommon. This 
has lead to the hypothesis that the predominant strain  were varying from place to 
place and time to time.  
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3.1.2 Ribotype identification by Capillary Sequences PCR and the contrast with 
gel PCR: 
 
Recently, the identification of etiologic agent techniques has been developed, and 
this gives microbiologists new equipment for molecuar biology typing methods 
which assist in the identification of microorganisms. Polymerase Chain Reaction 
(PCR) ribotyping is used to type many organisms because it is fast and simple 
(O’Neill et al., 1996; Bidet et al., 2000), but its analysis by agarose gel 
electrophoresis made it difficult to reconcile the patterns from different laboratories. 
 
The PCR method of classification of C. difficile depends on the analysis of 
polymorphisms by specific oligonucleotide primers complementary to the 3' end of 
16s primer corresponding to base 1445-1466 of the 16S ribosomal RNA gene and the 
5' end of the 23s primer corresponding to base 1-20of the 23S ribosomal RNA gene. 
 
Indra et al. (2011) modified the work of Stubbs et al. (1990) on the capillary 
sequencing method by labelling the 16s primer with florescent dye and 23s without 
labelling and analysing the PCR fragment with capill ry gel electrophoresis, and this 
has provided a new angle on typing. The modified method achieved reliable peak 
patterns, dispelling the disadvantage of inter-labor tory comparisons of typing 
results, and significantly reducing the time and manpower required for PCR. In 
addition this technique can differentiate the fragment length 2b, which is better than 
1.5b, as the electrophoresis requires disconnected fragments (150-650b) to accurately 
identify the size of a fragment permitted to distinguish seven subgroups for the C. 
difficile 014 ribotype. 
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3.2 Material and methods: 
 
C. difficile strains were isolated and identified, beginning with an anti-toxin test 
(ELISA) for stool samples which was completed by Dr. Surekha Reddy and cultured 
in cooked meat broth. A subculture on blood agar and/or CCEY media was then 
carried out for morphology characters, as well as an ultraviolet test, a gram stain, 
motility investigation and DNA extraction.  
 
3.2.1 Bacterial isolates: 
 
Patients’ stool and environment samples were collected by Dr. Surekha Reddy from 
the surgical unit at the Western General Hospital, Edinburgh; there was no 
interaction between the researchers and the patients selected for this study, as this 
was a blind study. 
 
A total of 140 C. difficile isolates were collected from patients’ stools (n=89), and 
from their close hospital environment: floors, furniture and hospital equipment 
(n=51) during 2009. Pure cultures were stored in cooked meat broth.  
 
 
3.2.2 Visual investigation:  
 
• Ultraviolet tests were set up by exposing the bacterial growth to UV light and 
observing the yellowish shine of the colony. 
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• Gram stain was made for all strains, followed the procedure of Practical Medical 
Microbiology (1989, 14th edition, p. 41-42). Also cnfirmed the Gram positive 
roads and peripheral spores.   
 
• Motility was investigated using a hanging drop test, prepared by emulsifying a 
bacterial colony in normal saline, dispensing a drop on coverslip and turning it 
upside-down on the slide with a well; this was then investigated by a phase 
contrast microscope.   
 
3.2.3 DNA extraction: 
 
C. difficile isolates were subcultured on horse blood agar plates nd incubated for 24 
hours at 37°C in an anaerobic work station (Mark 3, Don Whitley Scientific, Shipley, 
Yorkshire). Five bacterial colonies were then emulsified and extracted, as described 
in Section 2.1.7.2, following the method promoted by O'Neill et al., (1996). 
 
3.2.4 PCR Ribotyping: 
 
PCR ribotyping was originally described by O'Neill et al. (1996) and adapted for 
analysis by the capillary gel electrophoresis method, according to Fawley et al. 
(2008). The 16S primer was labelled with carboxy-fluorescein (FAM) fluorescent 
dye at the 5’ end, as described by Indra et l. (2011), in order to identify and quantify 
the PCR product peaks by the sequencer (16S= P5 5'-GCG CCC TTT GTA GCT 
TGA CC-3'/ 23S= P3 5'-CTG GGG TGA AGT CGT AAC AAGG-3') (from 
Integrated DNA Technology, or IDT). 
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The amplification procedure involved initial denaturation at 95°C for 5 mins, then 25 
cycles of amplification with denaturation at 95°C for 60 secs, annealing at 55°C for 
60 secs, an additional 90 secs at 72°C, and finally 5 mins at 72°C. The PCR products 
were stored at -70°C if necessary before dilution.   
 
The amplified DNA was diluted 1:10 by nuclease-free distilled water, then diluted 
1:10 by sample diluents (HiDi formamide 995µl + LIZ-600 size Marker 5µl). This 
product was stored at 4°C until being sequenced by a 3730 DNA analyser at the 
GenePool Group, Edinburgh University.  
 
The fifty standard strains used in this study were from the MPRL collection and Dr 
Derek Farley’s collection from Belfast Health and Social Care Trust, and were as 
follows: 001, 002, 003, 005, 009, 011, 012, 014, 015, 017, 020, 023, 026, 027, 029, 
032, 035, 038, 039, 046, 053, 054, 056, 057, 059, 064 69, 070, 072, 075, 078, 081, 
087, 092, 095, 103, 104, 106, 111, 117, 119, 120, 15 26, 131, 137, 185, 186, 200 
and 210. They were originally typed by conventional PCR with agarose gels, and 
confirmed by capillary gel electrophoresis.  
3.3 Results: 
 
This study investigated 140 C. difficile particular isolates from hospitalised surgical 
patients (n=89) and their environment (n=51) in theW stern General Hospital, 
Edinburgh. These isolates were stored in a bijoux tube containing cooked meat broth 
and subcultured on blood agar into characterised colonies, examined for yellowish 
shine under UV light and subjected to a gram stain and DNA extraction for PCR. 
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Image A reveals that the C. difficile character colonies on blood agar ware not bright, 
but were glossy, stumpy and curved, had irregular edges which were sometimes 
broad, were non-haemolytic and had a diameter ranging between 1 and 3mm; this 
was also the case on the CCEY agar. The growth had a characteristic penetrative 
smell. 
 
The Gram stain image (Figure 3.2) presented a blue colour for C. difficile rods, and 







The C. difficile colony was identified by Capillary Sequencing Electrophoresis, 
which identifies strains by the patterns produced (size and location of the peak) by 
the PCR products (Figure 3.3). 
Figure3.1: presented C. difficile colony on CCEY 
and blood agar.   
Figure 3.2: Gram stains of 
C. difficile cells and 





Figure 3.3: The Electrophorogram displays fluorescent signal intensities from Capillary 
Sequencing PCR by fluorescent labelled primers for 9 C. difficile standard isolates (001, 
020, 106, 039, 015, 046, 002, 014 and 023). The y-axis show the signal intensities in 
Relative Fluorescent Units and x-axis for basepair sizes of fragments.The figure shows 
overlay view to compare easily several sample traces t once.  
 
 
 L               001    012        L       1       2         3          4          5         6         L 
Figure 3.4: Images of PCR ribotyping by agarose gel el ctrophoresis. There are two 
standards: ribotype 001 and 012 with examples of 001 (tracks 1-3); 012 (track 5) and an 
unidentified type (track 4). L = size ladder (100-100bp). 
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Analysis showed that 15 different PCR ribotypes were detected, with just four of the 
most frequent ribotypes representing about 70% of the study isolates. Overall, the 
epidemic strain ribotype 001 was the most frequent isolate, with a total of 74 isolates, 
about two thirds of which came from stool samples and 24 from the environment. 
These were followed by ribotype 020 (10 isolates), divided equally between patient 
and stool. Ribotype 106 was next with eight isolates (three from patients and five 
from the environment), then ribotype 039 with six isolates (two from patients and 













Notably, the hypervirulent ribotype 027 was absent in this study. Ribotype 002, 
which was found to be the most common ribotype by Taori et al. (2010), was also 
 Environment Stool Total Percentage 
Total 51 89 140 100 
001 24 50 74 52.8 
020 5 5 10 7.4 
106 3 5 8 5.7 
039 4 2 6 4.3 
015 1 3 4 2.8 
046 2 2 4 2.3 
002 0 4 4 2.3 
014 2 1 3 2.1 
005 0 3 3 2.1 
023 1 2 3 2.1 
012 1 1 2 1.4 
032 1 1 2 1.4 
081 1 1 2 1.4 
003 0 1 1 0.7 
064 0 1 1 0.7 
Unknown 4 9 13 9.3 
Table 3.1: Frequencies of C. difficile ribotypes 
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uncommon, with only four isolates in this study which originated only from stools; 
005, 003 and 064 ribotypes were also isolated from stools only. 
 
 
The agarose gel technique was used with some isolate  to compare the results to 
CGE and the variation can be observed between the agarose gel (Figure 3.4) and 
CGE (Figure 3.3). The noticeable difficulty when differentiating between the bands 




The world at the beginning of twenty-first century has been challenged by CDI 
caused by C. difficile, especially in the elderly and compromised individuals such as 
the hospitalised community. Many strains have been isolated from infected persons. 
These strains varied in their ferocity depending on the virulence factors of the 
Figure 3.5: Distribution of ribotypes 
 90 
etiologic agent. The prevalence of ribotypes varies from time to time and place to 
place due to unidentified reasons. However, this study indicates the view of the 
hospitalised endemic C. difficile ribotype, which reflects the general picture of C. 
difficile epidemiology. 
 
The epidemiological study attempts to predict the future, through analysis of past and 
present accident data. It also highlights the hospital load of the infectious diseases. In 
this study, out of 140 isolates 15 ribotypes were id ntified, and the epidemic is of 
ribotype 001. These results indicate the changing prevalence, as the same ribotype 
featured in the Mutlu et al. (2007) study, and ribotype 002 was present in Taori et 
al.’s (2010) results. The HPS records in 2011 also indicated that ribotypes 106 and 
001 are the most prevalent in Scotland, while ribotype 027, which was the most 
hypervirulent strain, is retreating except for in some cities in Scotland and various 
countries in Europe (Kuijper et al., 2008). Moreover, the C. difficile Ribotyping 
Network (CDRN) indicated that the frequency of ribotype 027 had decreased in the 
2008-2009 report in England compared to 2007-2008 (Freeman et al., 2010).  
 
In this surveillance, 89 C. difficile isolates were collected from patients’ stool 
samples along with 51 isolates from different types of hospital environments. The C.
difficile ribotype 001 dominates in this study, with 74 isolates, followed by 10 
isolates of ribotype 020 and eight of ribotype 106. The other ribotypes were 
negligible. It is apparent that the source of C. difficile may have had some effect on 
increasing the repetition of the non-hyper-virulent ribotypes.  
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The epidemic strain ribotype 001 had soared in this study by about 53%, a third of 
which instances were related to hospital environments, while eight isolates of the 
epidemic ribotype 106 appeared in the search, five of which were from stool samples 
and three from the hospital environments. while 001ribotype represented by 19% in 
the Wiuff et al. (2011) study.  
 
Some studies have suggested that other ribotypes exceed the frequencies of 027 
ribotype, such as 078 in some European countries (e.g. the Netherlands) in 2007, 
compared to 2005, in which period 027 ribotype decreased from 27% to 1% and the 
prevalence of 078 ribotype jumped from 3% to 13% (Rupnik et al., 2008).  
 
However, in previous studies in Scotland, Taori et al. (2010) indicated that ribotype 
002 was the most frequent strain, although only four isolates in this study were from 
stools. However, Solomon et al. (2011) suggested that ribotype 027 is the most 
prevalent ribotype (18.8%), followed by 001 (15.8%) in their study in the Republic 
of Ireland. 
 
On the other side of the world, in Taiwan, Lin et al. (2011) investigated 130 isolates 
presented during the period 2001-2009 that NAP1 027ribotype did not expose. 
Additionally, Huang et al. (2010) stated that the predominant epidemic ribotype in 
Fudan University Hospital, Huashan, China, was 017, followed by 001, between 
December 2008 and May 2009. 
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Coia (2009) recorded that the Scottish Clostridium difficile Reference Service results 
for characterization by PCR ribotyping testing of 530 isolates in the period 
November 2007-August 2009 indicated that 75% of isolates related to 106, 001 and 
027 ribotypes, and hypothesized that these results were one of the natural reasons to 
create the new endemics ribotype of the C. difficile infection. 
 
There is a lack of knowledge about the frequency rate of CDI by ward specialties in 
Scotland. However, Smyth et al. (2008) studied the infections incidence in hospital 
wards, and indicated that the prevalence of C. difficile was 0.69% in the general 
surgical word and 1.09% for MRSA in four countries studied (England, Wales, 
Northern Ireland and the Republic of Ireland) during February 2006 to May 2006. 
However, this study failed to mention the ribotypes n cessary to identify the source 
of infection.  
 
Accurate identification tools used in searches have ssisted microbiologists to 
correctly define diagnoses. Nowadays, however, the PCR ribotyping has become the 
standard typing method for C. difficile in Europe, despite there being no international 
unified type strain library (Aspevall et al., 2006); this practice can be used with other 
molecular typing techniques to divide strains into subgroups.  
 
Although the agarose gel electrophoresis PCR technique is cheap and easy to apply, 
there can be poor resolution of fragment size analysis compared with CGE, which is 
the reason for this study. Indra et al. (2011) indicated that using CGE by labelling 
only the primer 16s by FAM dye to distinguish ribotypes is a more reliable and more 
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sensitive method, saves time and makes it easier to compare patterns between 
laboratories. The other benefit of labelling only the 16s primer is the avoidance of the 
double peaks which is necessary in routine work. 
 
The lack of standard ribotype collection can lead to ifferent nomenclatures, but this 
should be avoided and known standards shared. The website http://webribo.ages.at 
(accessed Sept 2012). offers automatic analysis and comparison of the Clostridium 
difficile capillary-sequencer-based PCR-ribotyping-data, andsimplifies laboratory 
PCR-ribotyping methods. Thus, the continuous investigation of stool and 
environmental samples to detect and analyse C. difficile is required to predict 
outbreaks. The provision of accurate tools is also essential in proper laboratories.  
 
A weakness in this study was that the ribotype distribu ion may have been influenced 
by the sample collection as the samples came from a single unit in one hospital. 
 
To conclude, the predominant C. difficile ribotype in the South Eastern of Scotland 
was 001ribotype, and the predominant ribotype changed time to time and place to 
another. The spores were presented in hospital environmental as a reservoir to spread 

































4.1 Introduction : 
 
The substantial global increase in life-threatening C. difficile infections (CDI) has 
become a major problem for healthcare organisations. C. difficile infection is a well-
known cause of diarrhoea in geriatric patients and is associated with broad-spectrum 
antibiotic use (Dallal et al., 2002).  
 
The C. difficile spore is considered to be the main source of CDI. These spores are 
resistant to heat and normal antiseptic detergents. C. difficile is also  drought-tolerant 
and may be difficult to remove from the surfaces of instruments. It has been isolated 
from different environments, such as lavatories and the surfaces of furniture in 
hospitals (Rupnik et al., 2009; Lin et al., 2011). Al-Saif and Brazier (1996) state that 
the C. difficile isolated from cats’ tails, pets, soil and water is indicative of the 
distribution of C. difficile throughout communities and in healthcare buildings. 
 
Communities in developed countries are exposed to many predisposing factors which 
may lead to CDI infections, such as the uncontrolled use of antimicrobial treatment 
and the increasing use by elderly individuals of new risky processes such as 
radiotherapy and chemotherapy to treat malignancies and tumours (Coia, 2009). In 
Scotland, CDI cases underwent an approximately tenfold increase between 1988 and 




Changes in the predominant types and their resistance to antibiotics have also 
occurred. Antimicrobial use is one of the most signif cant selective pressures that 
affects the change in the incidence of the different strains that cause C. difficile 
infection (CDI). Access to up-to-date information on patterns of resistance to 
antibiotics is therefore important (Taori et al., 2010). 
 
4.1.1 Virulence factors of C. difficile:  
 
The virulence of C. difficile depends on its ability to produce toxins. Strains are
likely to be selected by their resistance to antibio cs. Antimicrobial resistance 
patterns were related to the tcdC regulatory locus gens and consequent hyper 
production of toxins A, B and binary toxin (CDT) (McDonald et al., 2005). Lin et 
al., (2011) acknowledge that hyper-virulency is relatd o one or more of the genes 
tcdA, tcdB and cdtC.  
 
The other factor that assists CDI is disruption of the bowel microbiota by broad 
spectrum antibiotics that a C. difficile-colonised colon can tolerate. Impaired 
individuals, for example pregnant women or patients with compromised conditions, 
are more vulnerable to CDI (Balassiano et al., 2012). In addition to bacterial cell wall 
components, such as SLPs or flagellar proteins, hydrol tic enzymes and putative 
capsules also have a role in infection (Dingle et al., 2011). 
 
Coia, (2009) and Wiuff et al., (2011) suggest that in the case of microbial virulent 
and pandemic strains, antimicrobial resistant strains could lead to the formation of 
endemic subtypes such as the 106 and 001 ribotypes of C. difficile. The Scottish 
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Clostridium difficile Reference Service identified 530 ribotyped clinical solates of C. 
difficile and investigated their antimicrobial susceptibility between November 2007 
and August 2009. They were found 90% of isolates were r sistant to clindamycin 
and fluoroquinolones, all isolates were susceptible o vancomycin and metronidazole.  
 
In the past, clindamycin was the first antibiotic to be associated with CDI. 
Widespread use of penicillin was then found to be a predisposing factor for CDI. 
More recently, the third generation of cephalosporins and fluoroquinolones have 
been implicated as risk factors for CDI (Wiuff et al., 2011). 
 
4.1.2 C. difficile antimicrobial therapy: 
 
The Society for Healthcare Epidemiology of America and the Infectious Diseases 
Society of America (SHEA/IDSA) guidelines recommend oral metronidazole for 
mild and moderate cases of CDI, or oral vancomycin for severe cases following 
unsuccessful antimicrobial treatment. However, the European Society of Clinical 
Microbiology and Infectious Diseases treatment guidance document for CDI advises 
the use of teicoplanin, a glycopeptide, and vancomycin as supplementary oral 
therapy. Both American and European guidance favours ral treatment (Musgrave et 
al., 2011). 
 
Louie et al., (2011) advocate the use of the narrow spectrum macrocyclic antibiotic 
fidaxomicin as it is considered safe, there is a high level of active drug in the bowel, 
a low possibility of developing resistant strains and limited effects on intestinal 
microbiota. Moreover, it is associated with only a minor rate of recurrent CDI. 
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Alternative therapies include bismuth subsalicylate, rifamycin, nitazoxanide, 
tigecycline, linezolid and ramoplanin, as well as many non-antibiotic forms of 
treatment such as immunological methods, faecal transpl ntation and surgical 
procedures (Musgrave et al., 2011).  
 
The study aimed to investigate minimum inhibition con entration (MICs) and 
antibiotic resistance patterns for C. difficile isolates from surgical patients and 
associated environmental samples. The relationship between the sources of isolates 
and antibiotic susceptibility was also examined. 
 
4.2 Materials and methods: 
 
Colleagues from the surgical wards at the Western Ge eral Hospital in Edinburgh 
provided 89 stool samples during 2009 and purified C. difficile isolates were 
obtained from these samples. Also 51 pure cultures w re obtained from the 
environment of these patients. Pure cultures were stored in cooked meat broth for 
further investigation. 
 
This study followed guidelines set by the Clinical and Laboratory Standards Institute 
(CLSI), officially the National Committee for Clinical Laboratory Standards 
(NCCLS). MIC reference agar dilution methods (NCCLS 2004). Performance 
Standards for Antimicrobial Susceptibility Testing 2007) were used. 
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The isolates of standardised McFarland inocula were st aked onto pre-reduced 
Brucella agar plates supplemented with vitamin K1, haemin and 5% (v/v) horse 
blood (BD Biosciences, Oxford, UK). 
 
The control strains used in each batch in this study were C. difficile ribotypes 001, 
002, 012, 027, 078, and 106 from the MPRL collection. The agar dilution method 
was used to estimate the MICs for the six antibiotics (ampicillin, erythromycin, 
tetracycline, metronidazole, moxifloxacin and vancomycin). 
 
The break points in this analysis were erythromycin ≥ 8 µg/ml, tetracycline ≥ 16 
µg/ml, metronidazole ≥ 32 µg/mL, moxifloxacin ≥ 8µg /ml and vancomycin ≥ 32 
µg/ml, (following Taori et al., 2010) and ampicillin ≥ 32 µg/ml (from Taori et al., 




The MICs were assessed by agar diffusion as describd in Section 4.2. The image in 
Figure 4.1 shows the Brucella agar medium with horse blood, including antibiotic 
dilution and the growth of C. difficile isolates.  
 
4.3.1 Sensitivity to antibiotics: 
 
The susceptibility of 140 C. difficile isolates to the six antibiotics used in this study 
by determination of MICs is summarised in Table 4.1 and Figures 4.2 and 4.3. 100% 
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of isolates were sensitive to moxifloxacin, metronidazole and vancomycin. These 
results are generally compatible with Wiuff et al., (2011). However, whilst 100% of 
the environmental isolates were sensitive to tetracycline, more than 85% of isolates 
were sensitive to ampicillin and around 15% were resistant to erythromycin (Table 
4.1). 
 
Antibiotic Vancomycin Erythromycin Tetracycline Ampicillin Metronidazole Moxifloxacin 
Source of isolates envi stool envi stool envi stool envi stool envi stool envi stool 
Number of 
resistance isolates 
__   __ 42 70 __ 13 7 14 __ __ __   _ 
Number of 
sensitive isolates 
51 89 9 19 51 76 44 75 41 89 51 89 




Figure 4.1: Image of Brucella agar with blood 


























Figure 4.2: Percentage of antibiotics susceptibility of C. difficile isolates 
 
Figure 4.2 shows antibiotic susceptibility for C. difficile isolates from different 
sources. The chart shows that 74% of isolates exhibited resistance to erythromycin, 
whilst 100% of isolates were sensitive to vancomycin, metronidazole and 
moxifloxacin. More than 12% of isolates were resistant to tetracycline and 
ampicillin. 
 
4.1 Dominant ribotypes and MIC: 
 
The most frequent ribotype in this study was the epidemic ribotype 001. This strain 
illustrates susceptibility to vancomycin, moxifloxacin and metronidazole. There was 
no substantial variation between the 001 ribotype and the other ribotypes and no 




Table 4.2 shows the MIC50 and MIC90 for ribotype 001, which indicates that 50% 
of isolates were inhibited by 20 µg/ml of ampicillin and by 160 µg/ml of 
erythromycin. For tetracycline, metronidazole, moxifl acin and vancomycin, the 
corresponding figure was 5 µg/ml. The same results were observed in MIC90 for 
metronidazole and moxifloxacin. Ampicillin and erythromycin inhibit ribotype 001 
at concentrations of  160µg/ml for MIC90; the figure for tetracycline was 80µg/ml.  
































































































Figure 4.3: The histogram shows that  all C. difficile isolates are suscepitible to 
vancomycin, metronidazole and moxifloxacin, but some strains from the environment 
show resistance to erythromycin and tetracycline, while the stool strains show the 
highest resistant percentage to eryrthomicin. 
Antibiotic MIC 50 µg/ml MIC90 µg/ml Break point µg/ml 
Ampicillin 20 160 64 
Erythromycin 160 160  8 
Tetracycline 5 80  16 
Metronidazole 5 5  32 
Moxifloxacin 5 5  8 
Vancomycin 5 10  16 























Figure 4.4 This shows an almost normal distribution of ampicillin MICs values 
against ribotype 001 and a concentration of 20µg was the most effective, the Y error 
bars by 1 standard deviation and fixed value 4 with5%. 
 
Through the data from this study we can see that there were similarities in antibiotic 
susceptibilty between isolates from the hospital enviroments and the stool isolates, 
which suggests that the sources of C. difficile isolates were the same, and the hospital 




This study examined the susceptibility of 140 C. difficile isolates and found all 
isolates to be susceptible to vancomycin, metronidazole and moxifloxacin. The HPS 
2011 report found vancomycin and metronidazole to be compatible for all ribotypes, 
but 100% of ribotype 106 and 69% of ribotype 001 isolates were resistant to 
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moxifloxacin. Ribotype 020 had 28 isolates that showed 100% sensitivity in the HPS 
reports.  
 
Furthermore, the frequency of resistance by ribotype 001 isolates to erythromycin 
was 74%. Similarly, HPS reports show a figure of 71%, whilst Mutlu et al., (2007) 
found that 95.4% of ribotype 001 isolates were resistant to three or more antibiotics. 
Ribotype 001 is often related to multi-antibiotic resistant strains, which may partially 
explain its predominance in some studies (Taori et al., 2010). Furthermore, 100% of 
ribotype 106 isolates are resistant to erythromycin, but the ribotype 020 isolates were 
sensitive 100%. 
 
In this study, 7% of isolates were found to be resistant to tetracycline, whilst Barbut 
et al. (2007) indicated that for toxigenic strains 9.2% of isolates are resistant to 
tetracycline.  
 
No strain was resistant to all six antibiotics used in this study. Mutlu et al., (2007) 
found one isolate of ribotype 001 to be resistant to he five antibiotics studied. As 
incidence rates of CDI in Scotland have decreased (HPS reports 2011), multidrug 
resistance is not the only virulence factor in the C. difficile endemic. A number of 
other virulence factors, such as inducers of cytokines, binary toxins, surface layer 
proteins and sporulation, have been suggested as are in which further research is 
needed (Taori et al., 2010). 
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Table 2 shows that 50% of isolates were inhibited by 20 µg/ml of ampicillin and 160 
µg/ml of erythromycin compared to 32 µg/ml in 2005 results obtained by Taori et 
al., (2010), whilst tetracycline, metronidazole, moxifloxacin and vancomycin were 
inhibited by 5µg/ml. The same results were obtained i  MIC90 for metronidazole 
and moxifloxacin. During the period 1979-2004, the MIC50 (Taori et al., 2010) 
study obtained the same results for metronidazole, whilst the figure for tetracycline 
was 1µg/ml, for moxifloxacin 2µg/ml, and 1µg/ml for vancomycin. In addition, 
ampicillin and erythromycin inhibit ribotype 012 at  160µg/ml for MIC90 and 
80µg/ml for tetracycline. Lin et al., (2011) found the value for MIC90 for ampicillin 
to be 4µg/ml.  
 
Rupnik et al., 2009 and Lin et al., 2011 indicate that the C. difficle spores were able 
to contaminated  hospital's surfaces furnture, toile s and linen. The inferences of 
similarity in antibiotic susceptibility of stool and environmental isolates lead to 
suggesting that the C. difficile spores spread in hospital environments. 
 
The change in the pervasiveness of C. difficile and its susceptibility to antimicrobials 
could be due to numerous factors. Ongoing studies on the change in C. difficile 
ribotypes in hospital environments and their ability to induce cytokines, binary 
toxins, surface layer proteins and sporulation are required, which will have 

















CHAPTER V  IMMUNE RESPONSES TO C. difficile ANTIGENS 












A huge range of microorganisms inhabit the human bowel. The host mucosal 
immune system has the ability to differentiate between pathogenic and commensal 
organisms. The regular sampling of antigenic molecules from normal microbiota 
may be used to enhance specific IgA responses from mesenteric lymph nodes against 
symbiotic microorganisms. The IgA is then secreted to the mucosal layer in the colon 
to protect the intestine from microbial assault (Kinnebrew and Pamer, 2012).  
 
Viscidi et al., (1983) hypothesised that the production of antibodies is stimulated 
during childhood and continues into older age irrespective whether the body is 
exposed to the same pathogens or to alternative specie . 
 
The host immune response to C. difficile immunogenic molecules has been the 
subject of extensive research over the past decade. Kyne et al., (2000) found no 
significant difference between IgG and IgA levels in serum from CDI patients. 
Drudy et al., (2004) found no variation in the concentrations of IgG, IgM and IgA 
against S-layer proteins ofC. difficile in serum from patients, carriers and controls.  
 
Sanchez-Hurtado et al., (2008) examined the response of antibodies to different C. 
difficile antigens in symptomatic CDI patients, carriers andcontrols (non-colonised 
individuals). No noteworthy variation in IgM levels with all antigens between the 
three groups was found, while anti-lipocarbohydrate IgG was higher in controls. 
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Antibodies for other antigens were higher in symptomatic patients and carriers than 
in the controls.     
This study aimed to separate the C. difficile cell wall antigen SLPs, lipocarbohydrate 
(LC) and flagellar proteins from the five most frequ nt strains encountered in South 
Eastern Scotland. The objective was to test the hypot esis of immunogenicity of 
these C. difficile proteins by estimating IgG levels against these antige s in the 
community of Edinburgh and in hospitalised individuals and to determine the hyper 
immunogenic antigen. The hypothesis of repeated infection due to a lack of creation 
of antibodies was also examined. 
   
5.2 Materials and methods: 
 
5.2.1 Bacterial growth: 
 
Four of  most frequent C. difficile ribotypes in South Eastern Scotland (001, 002, 078 
and 106) along with ribotype 027, which is very uncommon locally, were grown 
anaerobically in PPY broth and used to extract SLPs, C and flagellar proteins.  
 
5.2.2 Extraction of SLPs, LC and flagellar proteins: 
 
The guanidine HCl method was used to extract SLPs from the five C. difficile 
ribotypes as described in Section 2.3.2.2. The extraction methods for flagellar 
proteins followed the procedure outlined in Section 2.3.4. Extraction methods for 
lipocarbohydrate (LC) were based on Poxton and Cartmill (1982) and Sharp and 
Poxton (1986) as described in Section 2.3.5. 
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5.2.3 PAGE preparations: 
 
Polyacrylamide gel electrophoresis was prepared as escribed in Section 2.3.6 to 
confirm the purification of proteins. 
 
5.2.4 Detection of IgG antibodies by ELISA: 
 
Detection of IgG antibodies was performed by ELISA. The procedure followed is 
described in Section 2.4.1.   
 
5.2.5 Serum samples: 
 
Samples were obtained from the MPRL collection originally obtained under ethical 
approval from the SE Scotland Blood Transfusion Servic  in Edinburgh (healthy 
blood donors) and patients in the Royal Victoria Hospital in Edinburgh: the latter 
were also used in the study by Sanchez-Hurtado et al (2008).  
 
The samples used in this study were divided into four groups:  
i. Donor samples were collected from healthy adult individuals from blood donors 
(230 samples).  
ii.  Controls were individuals who were culture-negative and toxin A/B negative (26 
samples) from the hospital community. 
iii.  Symptomatic samples were collected from patients wih cl nically diagnosed CDI 
by positive investigation for toxin A/B, stools and/or positive identification for 
PMC on colonoscopy (20 samples). 
iv. Carrier samples were collected from people who were culture positive for toxin 




5.3.1. Separation and purification of SLPs, LC and flagellar proteins: 
 
Separation of SLPs from different ribotypes presented two layers: HMW about 45 
kDa and LMW around 35 kDa of SLPs as shown in the images in Figures 5.I. 





5.3.2 Anti-cell wall markers and flagellar proteins IgG levels in the community:   
 
The three antigens of C. difficile from every isolate of the five ribotypes were 
exposed to the donor serum. Measurements of the level of IgG antibodies against 
antigens were evaluated by ELISA, with the values then divided into groups to 
demonstrate the distribution. Charts of the distribu ion of IgG against SLPs, LC and 
flagellar proteins in donors’ serum showed almost normal distribution for all antigens 
as shown in the Figures 5.IIa, 5.IIb, 5.IIc, 5.IId, 5.IIe, 5.IIIa, 5.IIIb, 5.IIIc, 5.IIId, 
5.IIIe, 5.Iva, 5.IVb, 5.IVc, 5.IVd and 5.IVe.  
Figure 5.I: Demonstrates the two SLPs bands for  ribotypes 001, 002, 027, 078 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.IVe: anti-106 SLPs IgG % in standard serum 
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These figures indicate that anti-106 SLPs and anti-001 SLPs accounted for the 
highest percentages. Table 5.1 offered statistical values as standard error of the mean 
(SEM) which was about 3.4 for anti-106 SLPs and 4.5 for anti-001 SLPs. The 
confidence interval at 95% was more than 6.0 for anti-027 SLPs and 9.7 for anti-
001SLPs, whilst the range of prevalence in all anti-SLPs ranged from 33 to 51. The 
coefficient of variation with the exception of the 002 ribotype was 0.8. 
 
Ribotype Statistical parameters for 
SLPs 001 002 027 078 106 
Range 47 33 36 33 51 
Variance 283.4505 168.9231 164.7778 154 194.882 
Standard deviation 16.836 12.997 12.8366 12.4097 13.96 
Coefficient of variation 1.0338 0.8123 1.0697 0.9797 1.0409 
Standard error of the mean 4.4996 3.4736 2.9449 2.925 3.3858 
95% confidence interval 9.7208 7.5043 6.187 6.1712 7.1776 
Upper 95% confidence limit 26.00653 23.50427 18.18703 18.83785 20.5893 
Lower 95% confidence limit 6.564903 8.495732 5.812967 6.495481 6.23418 
Table 5.1: Statistical values of distribution of anti-SLPs IgG in healthy donor serum 
 
The 95% confidence interval ranged from 5.7 to 7.8 in anti-flagellar IgG and from 
4.98 to 7 in anti-LC IgG. However, the coefficient variations were mainly around 







Ribotype Statistic parameters for flagellar 
001 002 027 078 106 
Range 40 38 35 31 33 
Variance 185.4505 152.5074 160.0074 108.1714 159.007 
Standard deviation 13.618 12.3494 12.6494 10.4005 12.6098 
Coefficient of variation 0.8362 0.9208 0.9432 0.6842 0.9402 
Standard error of the mean 3.6396 2.9952 3.0679 2.6854 3.0583 
95% confidence interval 7.8628 6.3495 6.5037 5.7596 6.4834 
Upper 95% confidence limit 24.14853 19.76123 19.91549 20.95963 19.8951 
Lower 95% confidence limit 8.422902 7.062296 6.908043 9.440368 6.92839 
Table 5.2: Statistical values of distribution anti-flagellar IgG in healthy donor serum 
 
For anti-LC IgG distribution, the coefficient of vari tion was between 0.7 and 0.99 
for the 001 and 106 ribotypes respectively. The most n rmal distribution was found 
in anti-027LC IgG.   
 
Ribotype Statistical parameters for LC 
001 002 027 078 106 
Range 32 26 36 39 34 
Variance 134.0659 94.0074 147.7574 176.4667 177.5074 
Standard deviation 11.5787 9.6957 12.1555 13.2841 13.3232 
Coefficient of variation 0.711 0.7229 0.9063 0.9322 0.9934 
Standard error of the mean 3.0945 2.3516 2.9482 3.321 3.2313 
95% confidence interval 6.6853 4.9851 6.2498 7.0786 6.8502 
Upper 95% confidence limit 22.97105 18.39685 19.66157 21.32858 20.26192 
Lower 95% confidence limit 9.600381 8.426676 7.161959 7.171416 6.561613 




5.3.3 Contrast between IgG level averages against SLPs, LC and flagellar in the 
community samples (healthy donors): 
 
Immune response results in donor's serum showed that the SLPs had the highest 
averages in all ribotypes, with the exception of IgG anti-flagellar, which exceeded 
the IgG anti-SLPs in the 027 ribotype (Figure 5.V). However, IgG anti-LC was the 
lowest for all five ribotypes (figure 5.V). On the other hand, the wider range of IgG 
concentration related to anti-LC was about 0.19. IgG anti-SLPs had the least 
variation (0.084) between the five ribotypes in an almost similar reaction (Table 5.4). 
Also there was a significant variation in immune response between different LC from 
different ribotypes. Donor serum had the best immune reaction to SLPs and flagellar 
proteins. 
 
Figure 5.V: Histogram showing the contrast between averages of anti-SLPs, anti-
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Statistical parameters SLPs average Flagellar average LC average 
Arithmetic mean 0.41068 0.374478 0.14975 
Geometric mean 0.4098 0.369562 0.104751 
Median 0.4069 0.385763 0.195575 
Range 0.0837 0.1656 0.2328 
Variance 0.000908 0.004525 0.0119 
Standard deviation 0.0301 0.0673 0.1089 
Coefficient of variation 0.0135 0.1796 0.7271 
Standard error of the mean 0.0374 0.0301 0.0487 
95% confidence interval 0.448085 0.0835 0.1352 
Upper 95% confidence limit 0.373275 0.458001 0.284955 
Lower 95% confidence limit 0.373275 0.290955 0.290955 
P value at DF = 5 0.0001 0.0001 0.0101 




5.3.4 Spread of IgG in C. difficile patterns: 
 
The spread of IgG levels for each pattern was displayed in a trend chart. The R- 
squared (R2) value was estimated to indicate the coefficient and effectiveness. The 
spread of IgG against the three antigens for different ibotypes is presented in figures 
5.VIa, 5.VIb. 5. VIc, 5.VId, 5.VIe, 5.VIIa, 5.VIIb, 5.VIIc, 5.VIId, 5.VIIe, 5.VIIIa, 5, 
VIIIb, 5.V.IIIc, 5.VIIId and 5.VIIIe. All values were represented in relation to all 
antigens in the study. 
 
Coefficient of R2 was determined in a statistical analysis that show the effectiveness 
of one changeable at predicting another variable. The R2 value ranged from 1 to 0 
and the higher the R2 value highlights the closer the values are to each other. 
 
The results showed that R2 ranged from 0.044 – 0.515, these results demonstrate th t 
the most influential results were found with the anti-LC IgG 106 ribotype from all 


























5.3.4.1 Anti-SLP IgG level distribution in donors:  
 
Figures 5.VIa-5.Vi show that the anti-SLPs for ribotype 106 values had the highest 
R2 value (0.38), whilst the lowest R2 assessed was for anti-SLPs 027 ribotype with 
0.27. 
 
5.3.4.2 Anti-flagellar IgG level distribution in don rs: 
 
Data in figures 5.VIIa-5.VIIe characterise that the anti-flagellar IgG level for 
ribotype 078 has the highest R2 value (0.31), whilst ribotype 002 had the smallest 
(0.27). 
 
5.3.4.3 Anti-LC IgG level distribution: 
 
The statistics in Figures 5.VIIIa-5.VIIIe show that there was a high degree of 
variation in R2 values, whereas R2 for IgG against LC from ribotype 106 distribution 
reached a peak of 0.52. Conversely, for anti-002 LC IgG levels R2 fell to 0.04.  
 
 
5.3.6 Comparison of immune response of patients, carriers, donors and controls 
to SLPs, LC and flagellar proteins from five dominant ribotypes: 
 
The serum samples used in this study were divided into four groups: symptomatic 
patients, carriers, controls and community donors, as described in Section 5.2.5. 
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The averages of anti-IgG were compared, as shown in Figures 5.IX, 5.X and 5.XI.   
These graphs data show that donor samples had the lowest degree of variation (0.76-
0.98) for the three antigens of five ribotypes, followed by the serum samples from 
the control group. For the symptomatic patients, the corresponding figures were 
between 0.1 - 0.219, more than five times the range obs rved in the donor samples.  
 
The highest average value occurred in symptomatic smples due to the three types of 
antigens: SLPs, LC and flagellar proteins. Statistical analysis of the differences in the 
means in symptomatic cases and donors indicated there was a significant difference 
between them (P=0.0345; degree of freedom D.F. = 5) as well with controls. On the 
other hand, the differences between symptomatic patients and carriers were not 
considered to be statistically significant (P= 0.73). The error bars correspond to the 












This study aimed to extract three antigens from the cell wall and flagellar proteins of 
the four predominant C. difficile ribotypes in South Eastern Scotland along with 027. 
The objective was to determine the suggestion that the C. difficile cell wall molecules 
were involve in systemic immune responses or not, by estimating the IgG level 
against these antigens in the people in the community i  Edinburgh and in 
hospitalised individuals. It also aimed to determine the immunogenic components 
from these three antigens and the relation between c ll wall antigens and virulence 
and to begin to examine the hypothesis that recurrent infection occurs due to a lack 
of antibody responses . 
 
The three antigens, SLPs, LC and flagellar proteins were found to exhibit 
immunogenic activities at different levels dependent o  the type of antigen and the 
source. 
 
O’Brien et al., (2005) claimed that anti-SLP serum was implicated in the protection 
of hamsters during lethal exposure to C. difficile infection. Kyne et al., (2001) 
recorded that the reduction in recurrent CDI in humans was associated with IgM anti-
SLPs. SLPs are  probably involved in the C. difficile colonisation mechanism in the 
host bowel and are the main immunogenic component of the C. difficile surface cell 
wall, which can be used in vaccination (Spigaglia et l., 2011). Calabi et al., (2002) 
suggested that SLPs have a role in microbial adhesion to epithelial cells and may 
lead to epithelial inflammation. Wright e al., (2007) argued that SLPs functioned as 
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immunodominant antigens when serum from six patients infected by C. difficile 078 
ribotypes against SLPs was analysed. Sanchez-Hurtado et l., (2008) claimed that the 
presence of IgG antibodies against SLPs was high in CDI cases compared to 
asymptomatic and control patients in their study. 
 
The results of this study were corroborated with previous results for SLPs, as 
immune reactions for all ribotypes-hypervirulent and on-hypervirulent – were 
found, but at different levels. The immune response of anti-SLP IgG level for 027 
were considerably higher in symptomatic serum compared to carrier, control and 
donor samples with a coefficient of variation (CV) of 0.0135. This outcome did not 
support Kyne et al. (2001) hypothesis, which states that patients colonised by C. 
difficile without associated diarrhoea developed a higher lev l of antibodies than did 
symptomatic patients.   
 
One of applications of the immune response studies against SLPs was preventing the 
host from developing CDI or at least decreasing colonisation by vaccination using 
SLPs (Kelly and Kyne, 2011; Sandolo et al., 2011; Péchiné et al., 2011).  
 
Research on the host immune response to flagellar antigens does not yet provide a 
full understanding of colonisation, pathogenicity and CDI prevention. Tasteyre et al., 
(2001) claim that the flagellated C. difficile isolates have the ability to adhere to the 
bowel mucus tissue of germ-free mice ten times more than non-flagellated strains, 
which is attributed to the flagella involved in bacterial adhesion to the mucus layer in 
vivo.   
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Péchiné et al., (2005) also examined C. difficile flagella proteins antibodies during 
the infection, the antibodies were at detectable lev ls 14 days after diagnosis of CDI. 
Furthermore, immunising with flagellar proteins in the mouse model, in combination 
with other surface antigens, was effective when inoculated by the rectal route and 
then exposing to a hypervirulent C. difficile strain. Colonisation was considerably 
lower in immunised mice compared to controls which received a PBS injection.  
 
Conversely, Dingle et al., (2011) rejected the hypotheses concerning the role of 
flagellar proteins in adherence and virulence when exposed to Caco-2 and epithelial 
cells in vitro. The wild-type strain C. difficile 630 was found to have lower adherence 
compared to mutant strains. As the mutant strains were more virulent in the hamster 
module, it was suggested that the flagellar proteins d d not affect a strain’s adherence 
and virulence. Dingle et al., (2011) propose that suppression of motility is a form of 
pathogenic strategy for CDI. 
 
The anti-flagellar IgG levels for the five most frequent ribotypes in Scotland were 
detected by ELISA after exposing to serum from sympto atic, asymptomatic 
carriers, controls and donors to C. difficile flagella proteins. The results indicate that 
the anti-flagellar IgG distribution in healthy donors was in an almost normal mode 
and was at a lower level compared to averages of SLPs for four ribotypes, with the 
exception of 027 ribotypes, which had the highest figures. It was also significantly 
high for 027 and 002 ribotypes in symptomatic patients compared to carriers, 
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controls and healthy donors with a coefficient of variation (CV) of 0.179. This may 
reflect the immunogenicity of flagellar proteins from 027 ribotypes. 
 
Poxton and Cartmill (1981) noted that the lipocarbohydrate polymers present in the 
C. difficile cell wall expressed immunogenic activity. Sanchez-Hurtado and Poxton 
(2008) noted that the combination of EDTA extract, crude LC with a suboptimal 
level of toxin had a considerably improved cytotoxic activity on Caco-2 cells and on 
cells from the Vero cell line in vitro. Sanchez-Hurtado et al., (2008) investigated 
anti-LC IgG levels in the serum of symptomatic patien s, carriers and control 
individuals using LC from endemic 001 ribotype and toxinotype 0. Results showed 
anti-LC IgG level in the controls was higher than in symptomatic samples and non-
symptomatic carriers. 
 
Lipocarbohydrate LC antigens from the five endemic C. difficile ribotypes in 
Scotland were challenged to serum samples from Edinburgh residents and 
hospitalised patients as well as controls to assess th  anti-LC IgG levels and compare 
these to anti-SLPs IgG and anti-flagellar IgG. The amount of anti-LC IgG in donor 
serum was lower than IgG for SLPs and flagellar proteins from all five ribotypes, 
although LC from ribotypes 027, 078 and 106 was about twice as high as anti-LC of 
001 and 002 ribotypes. For anti-LC IgG from 001 ribotype, similar results to 
Sanchez-Hurtado et al., (2008) were obtained. For LC ribotype 027, the symptomatic 
serum samples were the highest, with a significant v riation in anti-LC IgG levels 
compared to serum from other groups of individuals. The effect of LC varied 
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between ribotypes. The symptomatic serum response led to suggest that the LC may 
have a role in aspects of virulence of the strain and its pathogenicity.  
 
Recognition of the relationship between the lack of pr duction of specific antibodies 
after initial infection and recurrences was suggested by Drudy et al., (2004). The 
lower level of IgG in community individuals, controls and carriers compared to 
symptomatic patients does not indicate that production of antibodies has been 
disabled in these cases, but rather that the pre-existing level of antibodies in normal 
healthy donors and carriers is normally sufficient to allow the host to protect itself 
until it can resume the production of specific IgG antibodies after exposure to 
aetiologic agents.  
 
The weakness in the immune response of elderly people and immunocompromised 
patients was reflected in their being the most commn hosts of CDI, mainly because 
their immune systems were worn out as a result of ageing and severe or chronic 
illness.  
 
The paucity of information available about the bowel microbiota in the cases used in 
the study, as well as patients’ history, namely whether or not they had experienced 
recurrent cases of CDI or had undergone other treatm nts or operations that may 
have disrupted the immune system, should also be borne in mind and could clarify 
the incompatibility with some studies. On the other and, the sample size may have 
affected the statistical analysis of results.   
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To conclude, the relationship between host immune system and the appearance of 
illness requires further investigation. Immune responses to C. difficile cell wall 
components in normal healthy individuals and patients i  this study indicate the 
immunogenicity of SLPs, LC and flagellar proteins. SLPs from the hypervirulent 
ribotype 027 had had the highest immune response, as did the LCs and flagellar 
proteins, but with lower levels, indicating the relationship with virulence. The 
hypothesis of recurrent infection due a shortage of antibodies was not confirmed in 
this study as immune responses to non-hypervirulent strains varied between 
symptomatic cases and carriers. However, this hypotesis does not account for the 































As stated in chapter I, the disease symptoms caused by C. difficile are extremely 
wide-ranging. These signs range from mild symptoms to severe illness with difficult-
to-treat complications, and may be life threatening in compromised people.  
 
One of the primary barriers in the bowel is the innate immune system. The innate 
immune cells require immunogenic molecules for recognition and activation. The 
detection of foreign molecules by the presence of the mucosal layer in the bowel 
comprises three steps: the creation of an antimicrobial response, the stimulation of 
the epithelial cells and the activation of immune cells. 
 
This chapter is a comparative investigation of six cytokine levels which are enhanced 
by three antigens from five dominant C. difficile ribotypes in Scotland. The cell line 
was for in-vitro experiments and the cell wall antigen activities were compared to 
LPS for the production of cytokines.  
 
The aim of this study was to clarify the immunogenicity of the three antigens (SLPs, 
LC and flagella) from the dominant C. difficile strains, as well as assessing their 
effectiveness in the innate immunity by stimulating the THP-1 cell line to produce 
cytokines, and comparing their results to LPS as a control. The production levels of 
six cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-10 and IL-12) were estimated by ELISA, 
and verified which antigen was hyper immunogenic by stimulating cytokine 
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secretion. In addition, an attempt was made to clarify the role of these antigens in 
innate human immunity. 
  
6.1.1 Microbiota and the role of cytokines in controlling innate immunity: 
 
The human bowel is able to be colonised by an enormous number of 
microorganisms. The normal relationship between the host and the microbes is either 
symbiotic or commensal on the area of contact, but it may convert to pathogenicity. 
 
Caio et al. (2012) suggested that the symbiotic microorganisms have a role in the 
balance of the microbiota and in supporting the host via many functions. The 
symbiotic microbes were able to change the innate immune system from an inactive 
anti-inflammation level condition to an active position by continuous signalling from 
microbiota inhabitants. This causes the innate immune cells to move and respond 
rapidly to invasive aetiologic or damaged tissue indicators. 
 
The quick-recruitment innate immune lines are essential for an effective human 
response to gastrointestinal pathogens. The damaged epithelial tissues include 
antigenic molecules of the pathogen. After detecting the immunogenic molecules 
through cellular immunity in the bowel, pro-inflammatory mediators like cytokines 
are rapidly discharged, which is the primary response to infection. These cytokines 
play a role in inducing antimicrobial factors and activating immune cells. The pro-
inflammatory and regulatory mediators include TNF-α, IL-1-β, IL-6, IL-8, IL-10 and 
IL-12, which are secreted from leukocytes (Kinnebrew and Pamer, 2012; Lin and 
Karin, 2007).  
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6.1.2 Interleukin -β (IL-1-β):  
 
Cytokine protein (IL-1-β) is known as catabolin. The macrophage is the producer of 
IL-1β preprotein, and is then activated as active cytokine. IL-1β is involved in many 
cellular activities, such as cell proliferation, differentiation, apoptosis and 
inflammatory pain hypersensitivity (Pesce et al., 2011).  
 
6.1.3 Interleukin 6 (IL-6): 
 
IL-6 has multiple effects, as it is responsible forstimulating acute phase protein 
synthesis, and stimulates the production of neutrophils in the bone marrow. It also 
supports B cell growth and is antagonistic to regulatory T cells. IL-6 is relevant to 
many chronic diseases, including diabetes, and is suggested to have a critical 
involvement in the development of colon cancer and the pathogenesis of Kaposi 
sarcoma (Lin and Michael, 2007; Kristiansen and Mandrup-Poulsen, 2005).  
 
6.1.4 Interleukin 8 (IL-8): 
 
IL-8 is a chemokine produced by macrophages and other cell types, such as epithelial 
and endothelial cells. The endothelial cells store IL-8 in their storage vesicles. The 
essential role of IL-8 is the induction of chemotaxis such as neutrophils and 
granulocytes in its target cells, as well as attracting neutrophils to the site of 
inflammation (Wolff et al., 1998). 
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6.1.5 Interleukin 10 (IL-10): 
 
The effect of IL-10 is immunosuppressive and anti-iflammatory activity, in 
significant contrast to IL-6. IL-10 inhibits NF-kB activation through ill-defined 
mechanisms, and as a result inhibits the production of pro-inflammatory cytokines, 
including TNF-α, IL-6, and IL-12. Consequently, the other role of IL-10 is the 
inhibition of tumour development and progression, as suggested by Lin and Karin 
(2007). 
 
6.1.6 Interleukin 12 (IL-12): 
 
IL-12 is a pro-inflammatory heterodimeric cytokine. The dendritic cells (DC), 
macrophages and human B-lymphoblastoid cells were the creator of IL-12. IL-12 
plays an essential role in the activities of natural killer (NK) cells and T lymphocytes, 
as well as mediating the enhancement of cytotoxic activity. Its other function is the 
stimulation of the production of interferon-gamma (IFN-γ) and tumour necrosis 
factor-alpha (TNF-α) from T and natural killer (NK) cells (Hamza et al., 2010). 
 
6.1.7 Tumour necrosis factor-alpha (TNF-α): 
  
TNF-α is a cytokine produced by activated macrophages, inflammatory cells and 
tumour cells. It has a role in systemic inflammation and in stimulating acute phase 
reactions, and its essential role is the organisation of immune cells. The ability to 
induce fever and sepsis has been suggested as a TNF function, especially in chronic 




6.1.8 The core of E. coli LPS: 
 
Many immunological studies have used E. coli LPS as a control antigen because it is 
readily obtainable and due to its immunogenicity. LPS contains three parts: Lipid A 
(the endotoxic part), a core oligosaccharide and O-polysaccharide, which is the 
important antigenic component and is extremely variable. In contrast the Lipid A 
component is the major biologically active part and is limited in structure and 
conserved. However, the antibody response acts against oligosaccharide and O-
polysaccharide together (Gibbs et al., 2004), while the inflammatory response is due 
to Lipid A. 
 
6.2 Materials and Methods: 
 
6.2.1 The sandwich enzyme-linked immunosorbent assay (ELISA):  
 
The ELISA procedure, following the technique outlined in Section 2.4.1, is 
summarised in Table 6.1. 
 
Well contents Antigen Antigen diluent Serum Serum diluent Conjugate Substrate 
Blank (B) - + - + + + 
Antigen control (Ag) + - - + + + 
Serum control (S) - + + - + + 
Test (T) + - + - + + 
Table 6.1: Summary of the ELISA procedure 
 
6.2.2 THP-1 cell line:  
 
The THP-1 cell line was used, as described in Section 2.5, to estimate the activity of 
C. difficile on this part of the immune system. PMA (50ng/ml) was added as a 
supplement to induce differentiation.  
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6.2.3 Exposure of THP-1 to C. difficile antigens:   
 
The challenge procedure to cell wall antigens which is described in Section 2.6.3 was 
followed to enhance the THP-1 cell line in order to pr duce cytokines after induction 
with C. difficile antigens.  
 
 
6.2.4 Assessment and evaluation of cytokines: 
 
Primary and secondary antibodies dilutions, as well as standard cytokine 
preparations, were followed as in Section 2.6.4. The steps in the Materials and 




The in-vitro exposure of C. difficile antigens to leukocytes induced cytokine 
production. The cytokines were captured by  specific anti-cytokine antibodies via the 
ELISA technique. The cytokine concentration (ng/ml) was evaluated by converting 
the optical density reading of ELISA results to ng/ml using the standard curve given 
for all standard cytokines used in this study, and the calculation based on a line 
between the points.   
 
Three C. difficile antigens (SLPs, LC and flagella) from six dominant ribotypes (001, 
002, 012 027, 078, 106) were used in this study, as well as E. coli LPS as a control. 




6.3.1 Innate immune response: 
  
Figure 6.1 presents the leukocyte response when expos d to C. difficile antigens from 
six dominant ribotypes and LPS as a control by estimating cytokine production. The 
highest concentration of antigens was 50µg/ml, and PMA was used at 50ng/ml, 
which gave more detectable levels than when 10ng/ml of PMA was used.  
 
There was a large variation between the effects of the different antigens. The 
cytokines induced in the leukocytes cell line ranged b tween 4.7 ng/ml for TNF-α 
from LC of 027 ribotype and 109.1 ng/ml for IL-10 after being treated by SLPs from 
027 ribotype. The lowest effect of LPS was 14.5ng/ml for IL-8 secretion, and the 
maximum value was 43.3 ng/ml for IL-12. Generally IL-8 has the lowest level of 
induction. Nevertheless, TNF-α showed the smallest amount of secretion from the 
cell line when exposed to 027 ribotype flagellar proteins.   
 
6.3.2 Interleukin 1-β: 
 
The highest level of IL-1β was produced by treating with flagellar antigens of 
ribotypes 027, 078 and 106; generally IL-1β levels ranged from 11.14ng/ml to 
35.5ng/ml, and LC and flagellar from 012 ribotype had a similar effect on IL-1β 
production. SLPs gave around 20ng/ml from ribotypes 001, 012 and 078, while a 
level of 27ng/ml was reached with 027 ribotype, dropping to 13ng/ml with 106 
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Figure 6.2: Comparison between antigens of six ribotypes for stimuating IL-β 
production and LPS 
 
Figures 6.2a, 6.2b, and 6.2c present the relationshp between IL-1β production and 
increasing LC, SLPs and flagellar concentrations of the six ribotypes. The 
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LPS 50µg enhancement of induction of IL-1β exceeded that by SLPs from 001, 012, 
027, 078 and 106 ribotypes, as well LC from 001, 027 and 106 ribotypes. Also 
flagellar proteins from 001 and 002 ribotypes were lower than LPS activity. 
 
6.3.3 Interleukin 6: 
 
Generally, IL-6 has a higher result for SLPs than IL-1β and IL-8, but there was 
considerable variation between the effects on the antigens from different ribotypes; 
012 ribotype antigens (SLPs, LC and flagellar) consequently gave higher 
concentrations than the other ribotypes. On the other hand, IL-6 levels due to 
flagellar proteins from four ribotypes were superior to SLPs except for ribotype 012, 
and the IL-6 level ranged from 30ng/ml to 45ng/ml. IL-6 from LC ranged from 
20ng/ml to 42ng/ml. The control LPS antigen exhibited a higher value than SLPs 
from 002, 027, 078 and 106 ribotypes (see figure 6.3). 
 
Figures 6.3a, 6.3b and 6.3c illustrate the relationship between IL-6 production 
development and increasing LC, SLPs and flagellar concentrations of the six 
ribotypes. The highest amount was 50µg of antigen used to represent the highest 
effect on leukocytes to produce IL-6. The LC and SLPs from six ribotypes and LPS 
at 5µg stimulate IL-6 in the range 10-20ng/ml, but flagellar proteins from 002, 027, 
078 and 106 ribotypes effect exceed 25ng/ml of IL-6. 012 antigens have the greatest 
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Figure 6.3: Comparison between antigens of six C. difficile ribotypes stimulating IL-
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Figure 6.3c: Il6 production by flagella from six riboype and LPS 
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6.3.4 Interleukin 8: 
 
The production of IL-8 was generally weak for all C. difficile antigens in the study as 
well as for the control. The largest amount of IL-8 was related to flagellar protein 
from 002 and 001 ribotypes by about 27ng. LPS showed th  lowest influence; less 
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Figure 6.4: Comparison between antigens of six C. difficile ribotypes for stimulating 
IL-8 production  and LPS 
 
The relationship between concentration of antigens a d cytokines production are 
summarised in figures 6.4a, 6.4b and 6.4c. The lower concentrations of  C. difficile 
antigens effect on stimulating IL-8  remain less than 20 ng/ml and did not go beyond 
















































































6.3.5 Interleukin 10: 
 
Interleukin-10 has the highest production level in general, and in particular was 
extremely sensitive to SLPs from 027 ribotype (109. ng/ml). However, the flagellar 
proteins from 027, 078 and 012 ribotypes were at the lower level for stimulation of 
leukocytes to induce IL-10. Although LPS enhanced lukocytes to produce about 
34ng, this was still lower than all the C. difficile antigens except for LC and SLPs 
from 001 ribotype (see Figure 6.5).  
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Figure 6.5: Comparison between antigens of six C. difficile ribotypes stimulating IL-
10 production and LPS 
 
The study were compared the effect of the concentration of C. difficile antigens on 
production IL-10. The result were shown in figures 6.5a, 6.5b and 6.5c. These figures 
were illustrate that the 50µg of LC from 002 ribotype stimulate IL-10 production by 
more than 55ng/ml, although IL-10 was not detectable when was used 5µg of LC 
from 002 and 001 ribotypes.  













































































































 6.3.6 Interleukin 12: 
 
Figure 6.6 shows that the flagellar protein antigen from ribotype 106 clearly 
appeared to be the best at enhancing IL-12 production, followed by ribotype 078. 
However, leukocytes were not sensitive to SLPs for pr ducing IL-12. On the other 
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Figure 6.6: Comparison between six C. difficile ribotypes antigens stimulating IL-12 
production and LPS 
 
As for other interleukins the greatest stimulation was due to exposure to 50µg of 
antigens. However, the 5µg of SLPs from 001, 002, 01  and 078 ribotypes and also 
LPS were unable to enhance leukocytes to produce detectable amount of IL-12. As 























































































































Figure 6.7 illustrates the elevated effect of flagelar protein antigens from 106, 078, 
001, 012 and 027 ribotypes on leukocytes to generate TNF- α, but the LC remains at 
a steady level for virtually all ribotypes, and SLPs shows the lowest value, while LPS 
exceeds LC and SLPs at stimulating leukocytes to produce TNF-α.  
 
TNF response to different concentrations of antigens have been similar to other 
interleukins, which gave the highest concentration when exposed to 50µg of antigen 
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Figure 6.7: Comparison between antigens of C. difficile ribotypes stimulating TNF 
production and LPS 
 
 













































































































To sum up, ribotype 027 and SLPs influence on IL-10 production reached a peak of 
109 ng/ml. Ribotypes 027, 078 and 012 and flagellar proteins induced over 60 ng/ml 
in IL-10, and TNF-α production by ribotype 106 and flagellar proteins i  excess of 
60 ng/ml. However, SLPs from 012 and 106 ribotypes only moderately induced 
cytokine production. The LPS control antigen doesn't go beyond C. difficile antigens 
in terms of enhancing leukocytes except with SLPs and LC in IL-12 secretion. The 
maximum cytokine secretion occurred with IL-10 with SLPs and crude flagellar from 
027 ribotype. The optimum concentration of PMA used was 50 ng, and the highest 




This study was designed to investigate the immune activity of three kinds of cell wall 
molecules from six endemic C. difficile ribotypes. The immune activities were 
assessed by in-vitro stimulation of human leukocytes to produce cytokines after 
being challenged with immunogenic molecules. An attempt was also made to clarify 
the role of these antigens in innate human immunity, and to determine the hyper 
immunogenic fragment from the three molecules used in the study. 
 
O'Brien et al. (2005) accepted that the SLPs from different ribotypes were 
heterogeneous. Sánchez-Hurtado and Poxton (2008) and Wright et al. (2008) 
suggested the role of SLPs in CDI. Ausiello et al. (2006) suspected that C. difficile 
infections interrupt the inflammatory and regulatory cytokine stability, as it enhances 
the production of high volumes of IL-1β and IL-6 as well as IL-10 combined with 
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IL-12p70, and proposed that there is an opportunity for multi-component vaccines, 
including SLPs, for protection against CDI. Spigagli  et al. (2011) suggested that the 
SLPs from C. difficile 027 and 001 ribotypes give these ribotypes advantages in the 
pathogenesis of CDI. Noticeably, this study showed that the SLPs from 027 ribotype 
produced a much more elevated level of IL-10 than with other ribotypes.  
 
However, Bianco et al.’s (2011) study used SLPs from C. difficile with 027, 001 and 
012 ribotypes and evaluated the immunogenicity patterns by exposing SLPs to 
monocytes in order to produce IL-1β, IL-6 and IL-10. They supposed that the SLPs 
would stimulate the monocytes to discharge high quantities of IL-10, which indicates 
the role of SLPs in host immunity against C. difficile. But they recommended that the 
SLPs were not implicated in the rising severity of infection by hypervirulent endemic 
strains, because they discovered that the immunogenic activity of SLPs extracted 
from the hypervirulent epidemic C. difficile strain has a similar action to non-
hypervirulent strains.  
 
The common points were the contribution of SLPs to the human innate immune 
response and that SLPs stimulate immune cells to produce IL-10 in abundance; these 
results indicated the effectiveness of SLPs on the pro-inflammatory and regulatory 
immune response. However, the hypotheses that the typ  of SLPs affects the 
aggressiveness of hypervirulent ribotypes requires further investigation. Many 
factors may have caused this variation in the results of the study; they could be due 
to the variation in the concentration of the SLPs and PMA used in the study, the 
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purity of the SLPs and the time of exposure to the antigen, the leukocyte type or 
anything else that had not been noticed. 
 
Ramos et al. (2004) indicated that flagellin plays a role in microbial motility, 
adherence and pathogenicity. Tasteyre et al. (2001) studied the sticking activities of 
crude flagellin from pathogenic C. difficile on sterilised faecal tissue of mice, as well 
as the activity of flagellated strains. They recorded that  adhesion was elevated ten 
times higher in flagellated isolates than strains without flagella. C. difficile flagellar 
proteins in this study showed high stimulation with IL-10, TNF-α and IL-6. The 
flagellar proteins from 027 ribotype gave the greatest performance.  
 
In 1981, Poxton and Cartmill purified two types of cell wall carbohydrates from C. 
difficile; they suggested immunogenic activity for both molecu s and noted a 
symmetry of wall and membrane teichoic acid. Sánchez-Hurtado and Poxton (2008) 
studied the effect of lipocarbohydrate on enhancing the cytotoxicity of suboptimal 
levels of toxin A. Their results showed notable improvement in the activity on Caco2 
and Vero cells, which suggested that LC has a enhancing effect on toxin A activity. 
Claes et al. (2011) pointed out that the lipoteichoic acid stimulatory activity in the 
bowel immune response was not elevated. In this resea ch, lipocarbohydrate does not 
show a high effect on immune enhancement in terms of interleukin production 
except on IL-10 and IL-6, with moderate achievement.  
 
Interleukins 10 production was highly sensitive to the three antigens, and was 
stimulated more than the other interleukins in this study. Lin and Karin, (2007) 
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claimed that the IL-10 was recognised as being a regulatory interleukin, which has 
considerably divergent action compared to pro-inflammatory interleukins such as IL-
6 and TNF-α. The decrease in the pro-inflammatory cytokine leve  and the lower 
level of IL-1β for all three antigens may indicate the microbial infection strategy 
illustrated by symptoms, as IL-1β was being responsible for inflammation, pain and  
hypersensitivity (Pesce t al., 2011). In general, the elevated level of IL-10 by 
flagellar proteins and SLPs of 027 ribotype may support the hypothesis regarding 
aggressiveness, as 027 ribotype has a link to  hyper-virulence.  
 
To recap, the SLPs and flagellar proteins from the C. difficile cell wall were 
immunogenically active molecules, which subvert the r gulatory and pro-
inflammatory cytokines, and both were involved in the host innate immune response. 
The contribution of these in C. difficile infection is suspected, thus the involvement 
of these proteins in vaccines is acceptable. Also their coded genes may have a role in 
the probiotic effect of non-pathogenic bacteria such as Lactobacillus spp Although 
027 ribotype, SLPs and flagellar antigens were shown to elevate IL-10 production by 
human leukocytes, the hypothesis concerning the hypervirulent ribotype characters 
being responsible alone for the virulence require more investigation before it can be 


























This chapter summarises the conclusions that can be drawn from the studies 
conducted for this thesis, and proposes points that could usefully be expanded 
through further study on these subjects.  
 
As mentioned at the end of Chapter I, four main aims were being investigated: 
 
1. To determine the distribution of C. difficile ribotypes by capillary gel 
electrophoresis and distinguish the predominant ribotypes. 
2. To estimate the antibiotic susceptibility in the strains isolated above to six 
antibiotics (ampicillin, erythromycin, tetracycline, metronidazole, moxifloxacin 
and vancomycin) and detect the MICs for these six antibiotics against the C. 
difficile isolates.  
3. To determine the hypothesis of the immunogenicity of non-toxin antigens of C. 
difficile cell protein:  SLPs, lipocarbohydrate (LC) and flagellar proteins.  
4.  To verify the hypothesis that the SLPs, LC and flage lar proteins from C. 
difficile are involved in the host innate immune response and have a role in the 
virulence of the hypervirulent ribotype during the infection.  
 







Prevalence susceptibility of C. difficile ribotypes:   
 
Determining the prevalence susceptibility of C. difficile was complicated due to 
many factors being involved; some were related to the host and others to the 
aetiologic agents, and in addition the healthcare provider carried a percentage of the 
responsibility. 
 
The healthcare establishment is responsible for the condition of the community’s 
health, and its strategies offer protection for mankind. It is predominantly the elderly 
and compromised individuals who are the victims of CDI, either in the wider 
community or hospitalised individuals. Consequently, infection control and 
preventive medicine must play a significant role in protecting people. The continuous 
investigation of aetiologic agents such as C. difficile is required to predict outbreaks, 
along with developing the methodology to obtain truthf l results. Thus, novel 
methods of ribotyping, such as Capillary Gel Electrophoresis Sequencing PCR, have 
been developed; this is one of the recommended techniques to determine the 
epidemic strains as it is of a high quality and easy to work with, requires only a short 
time for investigation and standard data can be contributed from an easily obtainable 
website (Indra et al., 2011).  
 
Elderly people and compromised individuals were the most frequent group of people 
to be infected by C. difficile; this group is the most likely to be hospitalised and 
consequently to face nosocomial infection. Prevention begins by hand washing and 
isolation in hospital, and as the C. difficile ecology is wide and the spores survive 
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many harsh conditions, an effective disinfectant is recommended to clean surfaces 
and linens in hospitals, along with other infection control precautions which it is 
essential to pursue.  
 
Efficiency of symptomatic CDI patients in producing specific antibodies to 
immunogenic molecules of C. difficile: 
 
There has previously been a debate on whether or not cases of CDI have had the 
ability to create specific antibodies to C. difficile antigens. The ELISA results in this 
study indicated there were a variety of antibody quantities in the investigated serum 
samples without a minimum stage.  
 
There was no significant variation in antibody levels for LC and flagellar proteins 
between symptomatic and non-symptomatic cases. The control SLPs antigens from 
027 ribotype had a slightly higher response in sympto atic cases, but the donor- 
sampled antibody levels were much lower compared to other groups in the study, 
which was unexpected.  
 
The response which was not clarified was the carrier esponse, which had almost the 
same symptomatic level without developing symptoms. It was suggested that the 
carrier response was faster than the symptoms developed, or that they had recurrent 
infections, meaning their immune memory of the same antigens was still at a high 
level; alternatively there may have been some external factors not mentioned. 
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However, it should be recognised that the study estimated systemic antibodies, while 
the mucosal antibody levels were more pertinent to developing symptoms.   
 
Influence of C. difficile cell wall molecules in immune response: 
 
C. difficile toxins were the most effective factors in creating symptoms, but the other 
cell wall molecules supported the cytotoxicity affect. These cell wall and flagellar 
components could have disrupted the immune system while the invasion was 
underway, as well as being involved in the aetiologic adherence to epithelial cells. 
Therefore these may have a role in the immune response.  
 
The study outcome indicated the elevated response lev l to SLPs antigens of 
hypervirulent ribotype 027. On the other hand, the influence of SLPs from 027 
ribotype on leukocytes in enhancing cytokine production shows an increased IL-10 
level, which has an anti-inflammation influence as it uppresses pro-inflammatory 
cytokines and delays symptoms. This may explain the virulence of the ribotypes, as 
well as the effectiveness of possible vaccines to prevent infection. The other point is 
the role of this antigen in the probiotic method ofCDI prevention. The 
lipocarbohydrate proteins and flagellar proteins illustrate similar effects on IL-10 
production. 
 
To recap, elderly and compromised people are now challenged by multi-resistant 
aetiologic agents which causes CDI and these spread rapi ly worldwide; it also has a 
complicated set of multiple effects. This organism may have increased virulence 
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when faced with a challenging ecology, and employs a complicated strategy to 
invade the host cells. The study aim was to gain an overview of the prevalence of C. 
difficile ribotypes in surgical patients and environments, and to determine the 
changing nature of antibiotic susceptibility. In addition it was hoped to detect the 
systemic immune responses to cell wall molecules in patients and donors, and to 
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